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Abbreviations  
Å Ångstrom (1Å = 10
-10
 m) 
A, Ala alanine  
Ac acetyl 
 
Aca ε-aminocaproic acid 
ACN 
 
acetonitrile 
AMC 7-amino-4-methylcoumarin 
AMCA  trans-4-amidomethylcyclohexylamine  
Amba 4-amidinobenzylamid 
AMe aminomethyl 
Boc tert-butoxycarbonyl 
(Boc)2O di-tert-butyl dicarbonate 
BOP (benzotriazol-1-yloxy)tris(dimethylamino)phosphonium 
hexafluorophosphate 
 
Bz benzoyl 
C, Cys cysteine 
Cbz carboxybenzyl 
Cha β-cyclohexylalanine 
D, Asp aspartic acid 
Da Dalton 
Dab 2,4-diaminobutyric acid 
 
DCM dichloromethane 
DIPEA N,N-diisopropylethylamine 
DMF dimethylformamide 
DNV dengue virus 
E, Glu glutamic acid 
EC50 concentration of inhibitor required to reduce an effect to 50%. 
E. coli Escherichia coli 
ER endoplasmic reticulum 
ESI elektrospray ionisation 
Equiv equivalent 
F, Phe phenylalanine 
Fmoc fluorenylmethyloxycarbonyl 
Gua guanidino 
Gaba γ-aminobutyric acid 
GCMA trans-(4-guanidino)cyclohexylmethylamide 
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GMe guanidinomethyl 
H, His histidine 
h hour 
hAla(2-Pyr) 2-homopyridylalanine (2-amino-4-(pyridin-2-yl)butanoic acid) 
HBTU 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethylaminium 
hexafluorophosphate HOBt ydroxybenz triazole 
hPhe homophenylalanine 
HPLC high-performance liquid chromatography 
HSA human serum albumin 
IC50 inhibitor concentration required to reduce an enzyme activity to 50%. 
I, Ile isoleucine 
JEV Japanese encephalitis virus 
Ki inhibition constant 
K, Lys 
L, Leu 
lysine 
Leucine L liter  
M 
M, Met 
molarity (mol/L) 
Methionine MHz megahertz 
min minutes 
MS mass spectrometry 
Naph naphtyl 
Nle norleucine 
NMM N-methylmorpholine 
NMR nuclear magnetic resonance 
n.d. not determined  
N, Asn asparagine 
Orn ornithine, 2,5-diaminopentanoic acid 
OSu succinimide 
P, Pro proline 
Pbf 2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl 
PDB protein data bank 
Phac phenylacetyl 
pNA para-nitroaniline 
ppm parts per million 
PyBOP benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate 
Q, Gln glutamine 
R, Arg arginine 
Rf retention factor 
RFU relative fluorescence units 
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RT room temperature 
Sar sarcosine, 2-(Methylamino)acetic acid 
SPPS solid-phase peptide synthesis 
T, Thr threonine 
TFA trifluoroacetic acid 
TIS triisopropylsilane 
Tle tert-leucine 
Tris tris(hydroxymethyl)aminomethane 
V, Val valine 
W, Trp tryptophane 
WNV West Nile virus 
Y, Tyr tyrosine 
 
  
 10 
 
  
Table of contents 
11 
 
Table of contents 
Abbreviations .................................................................................................................. 7 
Table of contents ........................................................................................................... 11 
1 Introduction ............................................................................................................ 15 
1.1 Transmission .................................................................................................... 16 
1.2 Pathogenesis ..................................................................................................... 17 
1.3 Pathological symptoms .................................................................................... 17 
1.4 West Nile virus classification ........................................................................... 18 
1.5 Morphology and structure of the WNV ........................................................... 19 
1.6 Replication cycle .............................................................................................. 20 
1.7 Genome structure and processing of the polyprotein ....................................... 21 
1.8 The biological roles of the nonstructural viral proteins ................................... 22 
1.9 Substrate recognition site of the NS2B-NS3 protease ..................................... 24 
1.10 Antiviral strategies ........................................................................................... 25 
1.11 Known WNV NS2B-NS3 protease inhibitors.................................................. 26 
1.12 Crystal structures of the WNV protease ........................................................... 29 
2 Aim of work ............................................................................................................ 33 
3 Results and discussion ........................................................................................... 34 
3.1 Inhibitors containing decarboxylated P1 arginine mimetics ............................ 34 
3.2 Modification of P2 and P3 residues ................................................................. 39 
3.3 Modification of P4 residue ............................................................................... 44 
3.4 Combination of the best P4 and P1 residues .................................................... 46 
3.5 Selectivity studies............................................................................................. 46 
3.6 Stability test with trypsin ................................................................................. 47 
3.7 Structure of the WNV NS2B-NS3 protease in complex with inhibitor 77 ...... 48 
3.8 Second modification of P2 and P3 residues ..................................................... 52 
3.9 Incorporation of alkylated GCMA residues in P1 position .............................. 53 
3.10 Design and synthesis of cyclic inhibitors ......................................................... 56 
 
Table of contents 
12 
 
3.11 Determination of inhibitory constants .............................................................. 66 
4 Conclusion ............................................................................................................... 69 
4 Zusammenfassung .................................................................................................. 73 
5 Experimental part .................................................................................................. 77 
5.1 Reagents and methods ...................................................................................... 77 
5.1.1 Reagents and materials .............................................................................. 77 
5.1.2 Thin layer chromatography ....................................................................... 77 
5.1.3 High performance liquid chromatography (HPLC) .................................. 77 
5.1.4 Lyophilization ........................................................................................... 78 
5.1.5 NMR and mass spectrometry .................................................................... 78 
5.2 Enzyme kinetic measurements ......................................................................... 79 
5.2.1 Kinetic measurement with the WNV NS2B-NS3 protease ....................... 79 
5.2.2 Measurements with trypsin-like serine proteases ...................................... 80 
5.3 Synthesis ........................................................................................................... 81 
5.3.1 General synthetic procedures .................................................................... 81 
5.3.2 Synthesis of the intermediates ................................................................... 87 
5.3.3 Synthesis of inhibitors 23-39 containing different P1 residues ................. 95 
5.3.4 Synthesis of inhibitors 40-45 containing Phe(3/4-AMe) .......................... 98 
5.3.5 Synthesis of inhibitors 46-51 containing Phe(3/4-GMe) ........................ 100 
5.3.6 Synthesis of the inhibitors 52-53 containing Phe(4-Gua) ....................... 101 
5.3.7 Synthesis of inhibitors 54-75 modified in P4 position ............................ 103 
5.3.8 Synthesis of inhibitors 76-78 containing best P1 and P4 residues .......... 105 
5.3.9 Synthesis of P2 and P3 modified agmatine derivatives 79-88 ................ 106 
5.3.10 Synthesis of inhibitors 89 and 90 with alkylated P1 guanidines ............. 108 
5.3.11 Synthesis of linearpeptides 91-105 ......................................................... 109 
5.3.12 Synthesis of cyclic peptides 106-111 ...................................................... 111 
Table of contents 
13 
 
5.3.13 Synthesis of substrates 112-114 and related intermediates .................... 119 
5.4 Stability tests of peptides 91-105 ................................................................... 120 
5.5 Crystal structure determination ...................................................................... 121 
References .................................................................................................................... 122 
Publications ................................................................................................................. 135 
Acknowledgment ......................................................................................................... 136 
Erklärung .................................................................................................................... 137 
Curriculum Vitae ........................................................................................................ 138 
 14 
 
 
  
Introduction 
15 
 
1 Introduction 
The mosquito-borne West Nile virus (WNV) was first isolated in 1937 in Uganda as 
Smithburn tried to isolate yellow fever virus (YFV) from an African woman
1
 with 
suggestive YFV infection. The drawn serum from the infected woman was inoculated 
through the brains of ten mice, whereby only one mouse survived. Later studies 
demonstrated that the virus is pathogenic to mice by intracerebral, intranasal or 
intraperitoneal inoculation, while only a weak pathogenesis was found in mice by 
subcutaneous application. Rhesus monkeys were also intracerebrally and intranasally 
treated with the virus, upon which all infected monkeys developed fatal encephalitis. 
Virus neutralization studies showed immunological similarity between the new virus 
and the Japanese B encephalitis virus. A histological study demonstrated that the new 
virus is strictly neurotropic but produces lesions of the central nervous system, which 
differs from those produced by the other known neurotropic viruses. In 1940, Smithburn 
introduced the name West Nile virus for this new neurotropic virus, which was isolated 
from the West Nile district in Uganda.
1
 WNV infections were not considered to be 
serious until the 1990s despite sporadic cases and outbreaks of the disease in humans 
and horses, which occurred in Europe and South Africa since the 1960s.
2
 Individual 
cases have been also reported in the Middle East and Asia.
3
 However, the WNV became 
a major risk after the first big pandemic in Romania 1996, which was followed by many 
outbreaks in various European countries (Italy 1998, France 2000–2003), in South 
Africa and the Middle East. The first WNV infection in the American continent was 
confirmed in New York in September 1999. The virus spread very rapidly in 46 states 
through the US and in Canada.
4
 In 2012 in the US, 5674 cases of WNV infection in 
people, including 286 deaths, were reported to the CDC
5
 (Centers for Disease, Control 
and Prevention, US). Therefore, there is a high need to develop drugs against WNV 
infection and it is important to understand all aspects of WNV life cycle in developing 
effective prevention and treatment strategies. 
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1.1 Transmission  
The WNV proliferation takes place through circulation between two main vectors, birds 
and mosquitoes.
6
 Mosquitoes, mainly Culex species act as bridge-vectors transmitting 
the WNV into dead-end vectors, like humans or horses (Figure 1.1). As the female 
mosquito draws blood from the infected birds, the WNV crosses the mosquito´s midgut, 
and replicates in many tissues, mainly in the nervous system and salivary glands, 
developing nonpathogenic versions of the virus that persists for the normal life period of 
the mosquito.
7
 Birds that are members of the Corvidae family (mainly crows) are highly 
susceptible to be infected by the mosquitoes, whereby they serve as amplifying hosts.
8
 
A study on the infected North American birds in 1999 demonstrated that the American 
crows have the highest viremia titers among the domestic birds (10
10
 plaque-forming 
units/ml serum at the fifth day of the infection).
9
 Whereby, the WNV could be isolated 
from the brain, kidney, heart, spleen, liver, lung, intestine, esophagus, gonad, skin and 
eye of the dead crows.
10
 In addition to the main vectors, WNV could be isolated from 
many other dead-end hosts like humans, equines, rodents, reptiles, amphibians, felines, 
canines, bats and sea mammals.
11
 WNV could be also transmitted by non-mosquito 
ways like organ transplantation, blood transfusion, lactation, or by in utero infection.
12
 
 
Figure 1.1: Transmission cycle of the WNV (http://www.vetmed.wisc.edu/WNV/background.html). 
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1.2 Pathogenesis 
After an infected mosquito´s sting, the WNV is transmitted into humans and 
mammalians intradermally through mosquito´s infectious saliva. The virus replicates in 
the Langerhans cells of the skin, where the virus has been first injected.
13
 The infected 
Langerhans cells immigrate to the local lymph nodes, where the WNV cycle in the 
blood stream begins causing primary viremia,
14
 which is followed by the secondary 
viremia after its distribution in peripheral tissues like spleen and kidney.
15
 The WNV 
can be detected in the blood one or two days post-infection, while it could largely 
disappear by the seventh day after inoculation, accompanied with the appearance of 
IgM (Immunoglobulin M) neutralizing antibodies.
15
 WNV can cross the blood brain 
barrier (BBB) to the central nervous system mainly in children, elderly and people with 
impaired immune system.
16
 WNV is able to infect the spinal cord, brainstem, basal 
ganglia and neurons, causing meningitis or encephalitis.
17
 The mechanism, by which the 
WNV crosses the BBB to the CNS is still unclear. However, two contradictory studies 
reported about the role of the Toll-like receptors 3 (TLR3). Wang reported that TLR3 
knockdown mice are resistant to lethal WNV infections in comparison to normal mice, 
suggesting a positive role of TLR 3 in the pathogenesis.
18
 Quite the opposite, Daffis 
demonstrated a protective role of the TLR3 against WNV.
19
 
1.3 Pathological symptoms 
Approximately, 80% of WNV infections are asymptomatic, whereas the symptoms in 
the other cases range between mild fever (95% of the symptomatic cases) to 
encephalitis or meningitis.
6
 20% of the cases develop WNV fever accompanied with 
headache, weakness, vomiting and nonspecific symptoms like muscle or neck pain, 
confusion and slurred speech. These symptoms could last one month after infection.
20
 
Less than 1% of the infected people exhibit neuroinvasive disease with neurological 
symptoms including confusion, delirium, trouble walking, tremors, blurry vision and 
numbness in limbs or body, which could last for two months to one year after onset.
21
 
The tendency to develop neuroinvasive diseases increases in people with impaired 
immune system and elderly.
22
 Currently, there exists no specific antiviral treatments or 
vaccines against WNV infection. 
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1.4 West Nile virus classification 
WNV belongs to the family of Flaviviridea. The name is derived from the Latin flavus 
or yellow referring to Yellow fever prototype virus.
23
 The Flaviviridea family contains 
four genera; pestivirus, hepacivirus, pegivirus and flavivirus.
24
 The flavivirus genus is 
divided depending on the kind of transmission arthropod into tick-borne and mosquito-
borne viruses. The mosquito-borne viruses are further subdivided into three serogroups; 
Dengue (DNV), Yellow Fever (YFV) and Japanese encephalitis (JEV) virus serotype. 
The JEV serogroup contains the WNV species, which is further subdivided into the 
WNV and Kunjin virus.
25
 To sum up, WNV is classified in the Flaviviridae family, 
genus flavivirus, mosquito-borne, member of the JEV serogroup, grouped into the West 
Nile virus species, West Nile virus subtype.
23, 26
 (Figure1.2) 
Flaviviridae 
Pestivirus  Hepacivirus  Flavivirus   pegivirus 
     Mosquito-borne  Tick-borne 
Dengue (DNV) Japanese Encephalitis (JEV) Yellow Fever (YFV) 
    West Nile virus species  
   West Nile virus  Kunjin virus 
Figure 1.2: Pedigree of the WNV. 
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1.5 Morphology and structure of the WNV 
The WNV is a relatively small virus, that contains a nucleocapsid with icosahedral 
shape surrounded by a lipid bilayer.
27
 The nucleocapsid is composed of multiple copies 
of the C protein and the viral RNA. The surface of the virus is composed of two 
proteins, the envelope protein E and the membrane protein M. Envelope protein E 
mediates binding and fusion during virus entry into host cells.
27
 The E proteins are 
arranged in head-to-tail homodimers that lie parallel to the lipid, on the viral surface in 
the mature version of the virus (Figure 1.3). The membrane protein M is produced by 
furin cleavage from the immature premembrane protein prM. The immature virus is 
larger than the mature virus due to its spiky shape (~ 60 nm in diameter), and the 
surface is slightly bigger than the mature virus (~ 50 nm in diameter).
27, 28
 After 
cleavage of the prM-E by furin, the E protein changes the conformation forming a soft 
layer which lies in parallel to the lipid bilayer.
29
 However, the cleaved pr peptide 
remains attached to the E protein, preventing membrane fusion during virion release at 
the host cell surface. After the virion entry into the extracellular environment, the pr 
liberates the E protein at low pH at the trans-Golgi network, allowing the membrane 
fusion to occur in the next replication cycle.
30
 
 
Figure 1.3: Schematic representation of a flavivirus particle. Left: immature virion; right: mature virion 
(figure taken from Heinz et al.).
31
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1.6 Replication cycle  
The WNV replication cycle begins when the virus binds to the host cells via unknown 
receptors, possibly lectin DC-SIGNR (dendritic cell-specific intercellular adhesion 
molecule-3-grabbing nonintegrin)
32
 or integrin αvβ3.
33
 After binding to the host cells, the 
virus enters the cell via clathrin-mediated endocytosis.
34
 At low pH, the nucleocapsid is 
released into the cytoplasma after fusion with the endoplasmic reticulum (ER) in 
lysosomal vesicles.
32
 Afterwards, the viral RNA is translated into a single polyprotein.
27
 
Subsequently, the viral protease NS2B-NS3 and several host proteases cleave the 
polyprotein producing ten functional proteins.
27
 The viral RNA-dependent RNA 
polymerase (RdRp) within NS5, in conjunction with other viral nonstructural proteins 
and possibly cell proteins produces complementary minus strands from the viral RNA 
template. The minus strand RNAs serve as template for the synthesis of new genomics 
RNAs, (Figure 1.4).
35
 Assembly and arrangement of the new viral units take place in 
association with intracellular membranes and nascent virions transit through the 
secretory pathway, where furin mediates the final cleavage event of pr-M prior to virion 
release from the host cell surface.
30
 
  
Introduction 
21 
 
 
Figure 1.4: Life cycle of the West Nile virus; Step 1. Virion binding to the host cells. Step 2. Receptor-
mediated endocytosis of the virus. Step 3. Viral fusion with the endosomal membrane due to the low pH 
environment within the endosomal vesicle. Step 4. Uncoating and release of the genome into the 
cytoplasm. Step 5. The translation of the viral RNA into a single polyprotein, which is processed by 
NS2B-NS3 protease to generate mature proteins. Step 6. The NS proteins, including the viral RNA-
dependent RNA polymerase NS5, form the replication complex for the synthesis of full-length 
(+)ssRNAs. Step 7. The negative-stranded RNA serves as template for the synthesis of full length 
positive-strand RNA. Step 8. Encapsidation of the newly synthesized RNA with the viral capsid protein 
C, and virion assembly at the ER membranes. Step 9. Maturation of the virions through furin mediated-
cleavage of the protein prM to the mature membrane protein. Step 10. Mature virions are transported to 
the plasma membrane and released by exocytosis (figure taken from Suthar et al.).
36
 
1.7 Genome structure and processing of the polyprotein 
The WNV genome is a single-stranded positive-sense RNA of 11,029 base pairs, which 
contains a single open reading frame (ORF) of 10,301 nt.
26
 The open reading frame 
starts at the nucleotide 96 at the 5' terminus and stops 631 nucleotids before the 3' 
terminus.
37, 38
 The viral genome serves as mRNA, due to the positive polarity, and is 
translated immediately by the host ribosomal machinery upon release from the 
nucleocapsid.
27
 A single immature polyprotein precursor is produced by translation of 
the ORF, followed by co- and post-translationally procedures achieved by both host and 
viral proteases. 
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The polyprotein precursor is arranged in the following order from N- to C-terminus: C-
prM-E-NS1-NS2A-NS2B-NS3-NS4A-NS4B-NS5 (Figure 1.5).
23, 24, 26, 39, 40
 Host 
proteases cleave the polyprotein at the following junctions, C/prM, prM/E, E/NS1, 
whereas the viral protease (NS2B-NS3) is considered to cleave at the NS2A/NS2B, 
NS2B/NS3, NS3/NS4A, and NS4B/NS5 protein junctions.
41
 However, the viral 
replication can not begin until all single proteins are cleaved and released from the 
polyprotein precursor. Therefore, inhibition of the viral protease (NS2B-NS3) or host 
proteases could be an attractive target for the design of effective WNV antiviral 
therapies. 
 
Figure 1.5: Viral RNA structure and the polyprotein precursor (figure taken from Brinton et al.).
27
 
1.8 The biological roles of the nonstructural viral proteins 
The viral proteins NS3 and the co-factor NS2B are attached together to form a 
heterocomplex. NS3 is a large ~70 kDa protein, that contains two distinct enzymatic 
domains, a protease domain within the N-terminus
41-44
 and a helicase/ATPase domain 
within its C-terminus.
41, 43
 The helicase/ATPase domain participates in viral RNA 
genome replication in association with RdRP in NS5 by unwinding the double-stranded 
RNA intermediates, facilitating NS5 polymerase activity.
45
 The NS3 protease domain is 
a serine protease, containing the catalytic triad formed by residues Ser135, His51, and 
Asp75.
46
 The main role of NS3 protease is the catalytic processing of the polyprotein to 
generate the single mature nonstructural proteins (Figure 1.6).
41
 However, the viral 
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protease NS3 is inactive until it forms a complex with the cofactor NS2B. The NS2B is 
a small ~15 kDa protein, that contains a central hydrophilic domain (II) surrounded with 
two hydrophobic parts (I, III). It is proposed that the hydrophobic regions of NS2B 
associate the protein to the ER membrane.
24, 47-49
 
 
Figure 1.6: Schematic representation of the flaviviral polyprotein. Cleavage sites of the polyprotein by 
the viral NS2B-NS3 and by host proteases. To exhibit the artificial heterocomplex, the NS2B-NS3, is 
depicted in the enlarged section (figure was adopted from Lescar et al.).
50
 
To generate a stable complex of NS2B and NS3 for enzymatic studies and 
crystallography, an artificial sequence consisting of a (Gly)4-Ser-(Gly)4 sequence was 
introduced between both domains.
51, 52
 A crystal structure of the recombinant NS2B40-
G4SG4-NS3 protein domain has been resolved illustrating that NS2B40 wraps around 
NS3 protein in a belt-like manner.
46, 53
 This suggests that NS2B may function as a 
cofactor to NS3, facilitating the arrangement of the catalytic triad into an active 
conformation.
27
 
The other nonstructural viral proteins NS2A, NS4A, and NS4B are small, hydrophobic 
proteins and may facilitate the assembly of viral replication complexes and/or their 
localization on cytoplasmic membranes.
27
 NS1 is a glycoprotein with two conserved N-
linked glycosylation sites and 12 conserved cysteines that are necessary for the virus 
viability.
27
 NS5 is the largest and most conserved viral protein which is located at the C-
terminus of the viral polyprotein. The C-terminal portion of NS5 contains motifs 
characteristic of all RdRps.
54
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1.9 Substrate recognition site of the NS2B-NS3 protease  
Studies with a 9-mer peptide library confirmed the strong preference of the WNV 
protease for substrate sequences with basic amino acids in P1 and P2 position.
55
 
The used peptides were deduced from the cleavage sites in the immature WNV 
polyprotein and are summarized in Table 1.1. showing also the cleavage efficacies in 
percentage.  
Table 1.1: Used peptides for the characterization of the substrate specificity of the WNV NS2B-NS3 
protease. The sequences span the potential cleavage sites in the WNV polyprotein. The cleavage 
efficiency in percent is shown in parentheses.
55
 
Proteins WNV (cleavage efficiency, %) 
Capsid C protein Q0102KKR↓GGTA0109 (62) 
C/prM C0120AGA↓VTLS0127 (1) 
prM H0209SRR↓SRRS0216 (6) 
prM R0212SRR↓SLTV0219 (0) 
prM/E P0297AYS↓FNCL0304 (0) 
E/NS1 N0784VHA↓DTGC0791 (0) 
NS1/NS2A R1140VNA↓YNAD1147 (0) 
NS2A K1327EKR↓SSAA1334 (0) 
NS2A A1334KKK↓GACL1341 (31) 
NS2A/NS2B N1367RKR↓GWPA1374 (64) 
NS2B-NS3 Y1498TKR↓GGVL1505 (73) 
NS3Protein/helicase R1686KKQ↓ITVL1693 (4) 
NS3Protein/helicase K1700TRK↓ILPQ1707 (3) 
NS3Protein/helicase K1716RLR↓TAVL1723 (0) 
NS3helicase A1957QRR↓GRIG1964 (2) 
NS3/NS4A S2117GKR↓SQIG2124 (0) 
NS4A E2243KQR↓SQTD2250 (0) 
NS4A/NS4B A2266VAA↓NEMG2273 (0) 
NS4B/NS5 G2522LKR↓GGAK2529 (73) 
These data showed the preference of the NS2B-NS3 protease for substrates containing 
arginine as P1 residue, whereby one sequence with lysine in the NS2A protein was also 
accepted. Furthermore, a strict requirement for the presence of a basic P2 residue was 
found, whereby a lysine seemed to be preferred over arginine. Many efficiently cleaved 
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sequences contained an additional basic amino acid in P3 position. However, some 
substrates possessed also a neutral amino acid as P3 residue. 
Moreover, the protease showed a strong preference for glycine at P1' and P2' positions. 
However, the cleavage site between NS2A and NS2B containing a P2' tryptophan was 
also excellently cleaved.  
In conclusion, substrates with the consensus sequence X-K/R-R↓GG were optimally 
recognized by the WNV protease.
55
 
1.10 Antiviral strategies 
Presently, there is no specific antiviral treatment or vaccines against WNV infection. 
The most effective preventive measure is the avoidance of mosquitos’ bites. The only 
treatment available is supportive management.
6
 In severe cases, high dependency care, 
including ventilation, is required. Interferon alpha, ribavirin, and WNV-specific 
immunoglobulins from previously infected patients have also been proposed as antiviral 
treatments.
56, 57
 Several human vaccines are available for infections by related viruses 
like YFV, JEV and tick-borne encephalitis virus, which employ the high antigenicity of 
their prM and E proteins.
24
 Therefore, the prM and E proteins of the YFV vaccine strain 
were replaced with the WNV prM and E proteins in chimeric viruses, which have 
shown promise for vaccine development.
58
  
The different stages of the WNV replication cycle could be used to develop new 
antiviral therapies. One strategy is the blocking of the virus entry utilizing antibodies 
directed against the E protein, subsequently inhibiting receptor binding and thus 
preventing the internalization of the virion into the host cell.
59, 60
 Other treatments could 
be the inhibition of RdRp within NS5 and of the helicase activity of NS3, both 
approaches should prevent the synthesis of viral RNA.
59
 As previously mentioned, the 
host protease furin plays a major role in virion maturation. Therefore, the inhibition of 
furin or other host proteases, which are involved in the processing of the WNV 
polyprotein, could be an alternative therapeutic strategy.
59
 However, the blocking of 
host enzymes could result in nonspecific side effects due to the downregulation of 
normal physiological mechanisms. This problem could be overcome by the selective 
inhibition of viral targets. Therefore, the WNV NS2B-NS3 protease, which has a major 
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role in the processing of the polyprotein precursor, is an attractive target for new drugs 
against WNV. 
1.11 Known WNV NS2B-NS3 protease inhibitors  
Aprotinin is a nonspecific serine protease inhibitor and inhibits also the WNV protease 
with a Ki value of 26 nM. It is isolated from bovine lung and has a molecular weight of 
6512 g/mol consisting of 58 amino acids.
61
 Aprotinin was used in heart surgery with 
cardiopulmonary bypass to reduce bleeding by slowing down fibrinolysis through 
plasmin inhibition.
62
 It was withdrawn from the market due to side effects in 2008.
63
  
Various polypeptides composed of D-arginine residues have been reported as WNV 
protease inhibitors. Both, the undeca-D-Arg-NH2 and dodeca-D-Arg-NH2 possess Ki 
value of ~1 nM, whereas a relatively poor inhibition constant of ~ 500 nM was found 
for the hexa-D-Arg-NH2 analogue (Table 1.2.).
64
 
Table 1.2. D-arginine-derived oligopeptide inhibitors of the WNV NS2B-NS3 protease  
Comp. Ki (nM) 
(D)RRRRRR-NH2; hexa-D-Arg-NH2 478±20 
(D)RRRRRRR-NH2; hepta-D-Arg-NH2 41±18 
(D)RRRRRRRR-NH2; octa-D-Arg-NH2 17±11 
(D)RRRRRRRRR-NH2; nona-D-Arg-NH2 6±1 
(D)RRRRRRRRRR-NH2; deca-D-Arg-NH2 2±1 
(D)RRRRRRRRRRR-NH2; undeca-D-Arg-NH2 1±1 
(D)RRRRRRRRRRRR-NH2; dodeca-D-Arg-NH2 1±1 
Well-known warheads of serine protease inhibitors are aldehydes, boronic acids, and 
various ketone derivatives.65 Several tetrapeptides containing a C-terminal arginal or 
other aldehydes were reported by Knox with IC50 values range between 1 and 200 µM.
46
 
The most potent inhibitors and their IC50 of this series are shown in Table 1.3. 
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Table 1.3: Arginal inhibitors of the WNV protease 
Comp. aldehyde inhibitors  IC50 (µM) 
1 Bz-Nle-Lys-Arg-Arg-H 4.1 
2 Bz-Ala-Lys-Arg-Arg-H 0.7 
3 Bz-Phe-Lys-Arg-Arg-H 1.2 
4 Bz-Nle-Lys-Lys-Arg-H 1.9 
Later, additional arginal derivatives have been reported by Stoermer et al..
66
 The use of 
the sequence P4-Lys-Lys-Arginal provided strongly improved inhibitors, selected 
analogues are shown in Table 1.4.  
Table 1.4: P4-Lys-Lys-Arginal inhibitors of the WNV protease. 
Comp. P4 Ki (nM) 
5 2-naphthoyl- 41 
6 phenylacetyl- 9 
7 4-phenyl-phenylacetyl- 6 
8 3-methoxy-phenylacetyl- 11 
A HTS search for positively charged inhibitors that were able to mimic the bifurcated 
guanidine side chain of the P1 Arg residue led to the identification of the commercially 
available compounds 9-11, which inhibit the WNV protease with Ki values in the 
micromolar range (Figure 1.7).67 
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Figure 1.7: Inhibition of the WNV NS2B-NS3 protease by guanylhydrazones 
 A further screening of 32,000 small molecules provided two 8-hydroxyquinoline 
derivatives with Ki values of ~ 3 µM (12 and 13, Figure 1.8).
68
 Furthermore, compound 
13 was capable of inhibiting WNV RNA replication in cultured Vero cells with an EC50 
of 1.4 µM 
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Figure 1.8: 8-hydroxyquinolin-derived WNV NS2B-NS3 inhibitors. 
Various agmatine and agmatine-like peptidomimetic inhibitors of the WNV were first 
reported in 2011.
69
 Such peptides with decarboxylated arginine mimetics in P1 position 
have been originally used for the inhibition of the trypsin-like serine protease 
thrombin,
70
 urokinase
71
, factor Xa,
72
 factor VIIa,
73
 plasmin
74
 and the proprotein 
convertase furin, which contains a Ca
2+
-dependent subtilisin-like protease domain.
75
  
For the most potent analogue 2-(biphenyl)acetyl-Lys-Lys-agmatine a Ki value of 2 µM 
was found (Figure 1.9).  
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     56 ( Ki = 2 µM) 
Figure 1.9: 2-(biphenyl)acetyl-Lys-Lys-agmatine 
Moreover, some allosteric inhibitors of the WNV protease were identified by screening 
of a small molecule library. The found pyrazolyl benzoic acid ester derivatives inhibit 
the WNV protease with IC50 values of 0.1 µM (Figure 1.10).
76
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Figure 1.10: Pyrazolyl benzoic acid ester derived WNV protease inhibitors. 
So far, only limited progress has been achieved in the field of synthetic WNV protease 
inhibitors. However, meanwhile several crystal structures of the WNV protease are 
available, which will enable a more rational, structure-based inhibitor design in the 
future. 
1.12 Crystal structures of the WNV protease  
In the native WNV protease the NS2B forms a non-covalent complex with NS3. 
However, all crystal structures have been solved with various artificial protease 
constructs expressed in E. coli, whereby the used proteins contain a flexible linker 
segment of 9 amino acids, which covalently connects the relevant parts of the NS2B and 
NS3 domains.
51
 
In one of the known structures the WNV protease is inhibited by the natural inhibitor 
aprotinin. In contrast to small molecule inhibitors, aprotinin occupies with its 
P3-P4'-segment Pro-Cys-Lys(P1)-Ala-Arg-Ile-Ile all major binding pockets of the 
protease (2ijo.pdb)
63
 (Figure. 1.11). The catalytic triad of the WNV protease is formed 
by residues His51, Asp75, and Ser135, which are arranged in a similar manner, as in 
several other serine proteases of the S1 and S8 subfamily. The distance of the side chain 
oxygen of the catalytic Ser135 and the carbon of the P1 Lys carbonyl group is 
approximately 2.8 Å, which indicates that, the P1-P1' peptide bond in this complex is 
not cleaved.
63
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Figure 1.11: Crystal structure of the WNV protease in complex with aprotinin (2ijo.pdb). The surface of 
the NS2B and NS3 domains are colored in yellow and green, respectively. For better visualization only 
the P3-P4' segment (Pro-Cys-Lys-Ala-Arg-Ile-Ile) of aprotinin is shown. 
The comparison of the aprotinin complex with the inhibitor-free structure (2ggv.pdb) 
revealed that the WNV NS2B-NS3 protease can exist in two distinct conformations; the 
inhibitor-bound close conformation and the inhibitor-free open conformation. The 
major difference between these two structures lies in the conformation of the NS2B 
cofactor. In both inhibitor-free and -bound structures, the β1 strand of the NS2B have 
the same conformation, while the residues following Trp62 adopt a completely new 
conformation in the inhibitor-free protease.
63
 
In complex with inhibitor, the NS2B cofactor forms a belt that wraps the NS3 protein 
(Figure 1.12). In contrast, a new turn-and-a-half helix (α1) followed by an unexpected 
reversal of the protein chain is found for the NS2B in the inhibitor-free structure 
forming an enzymatically inactive open conformation
63
 (Figure. 1.12). 
Introduction 
31 
 
 
Figure 1.12: Stereo view of the two possible conformations of the NS2B cofactor. The NS3 of the closed 
conformation is shown in green and stabilized by the surrounding NS2B cofactor in red, forming the 
active protease. In contrast NS2B in the open conformation is shown in blue, where residues after Trp62 
point in a completely different direction, which results in an inactive protease, (figure taken from Aleshin 
et al.).
63
 
Furthermore, crystal structures of the WNV NS2B-NS3 protease in the closed 
conformation have been solved in complex with aldehyde-derived inhibitors. In the 
complex with Benzoyl-Nle-Lys-Arg-Arg-H (2fp7.pdb),
46
 the crystal structure revealed 
that the S1 pocket is surrounded by Gly151, Tyr161, Tyr150, Asp129 and the backbone 
of residues of Tyr130–Thr132. Asp129 is located at the bottom of the S1 pocket and 
binds to the positively charged arginal side chain (Figure 1.13), whereby Tyr161 makes 
π-cation stacking interactions with the same residue. The S2 pocket is dominated by the 
negative electrostatic potential originating from the backbone carbonyl oxygen atoms of 
NS2B residues Asp82 and Gly83 and the Oδ1 atom of Asn84. These atoms are close to 
the positively charged guanidinium group of the P2 arginine, which was also within 
hydrogen bonding distance to Asn152 of NS3. The P3 lysine forms two H-Bonds, to the 
backbone carbonyl of Phe 85 and to the side chain carbonyl of Gln86, otherwise its side 
chain and the P4 norleucine are largely solvent exposed.
46
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Figure 1.13: X-ray structure of the substrate-binding region of WNV NS2B–NS3pro, hydrogen bonds are 
indicated (dotted lines) (figure taken from Erbel et al.).
46
  
An additional structure was solved in complex with the aldehyde 2-naphthoyl-Lys-Lys-
Arg-H (3e90.pdb).
77
 The structure revealed that the carbonyl oxygen of the P1 aldehyde 
is attacked by the serine hydroxyl and forms a tetrahedral hemiacetal. Interestingly, this 
oxygen is oriented in different ways in the asymmetric units, which contains two protein 
molecules. In one structure, it is rotated away from His51 and points into the oxyanion 
hole, forming H-bonds with the main chain nitrogens of Gly133 and Ser135 
(Figure 1.14, a). In the second complex, the P1 carbonyl oxygen interacts via a H-bond 
with His51 (Figure 1.14, b).
77
 Only this second interaction was observed in the complex 
with Benzoyl-Nle-Lys-Lys-Arg-H, described above.
46
 
 
Figure 1.14 Two different binding modes of 2-naphthoyl-Lys-Lys-Arg-H in complex with the WNV 
NS2B-NS3 protease. (a) The P1 carbonyl oxygen interacts with the backbone nitrogens of Gly133 and 
Ser135 in the oxyanion hole, and (b) is alternatively directed towards His51 in the second complex, 
(figure taken from Robin et al.).
77
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2 Aim of work 
Currently, there are no vaccines or specific treatments for WNV infections available, 
despite an increased number of fatal cases worldwide. Since the West Nile virus 
NS2B-NS3 protease is essential for viral replication, it is a potential target for the 
development of new antiviral medicaments for the treatment of WNV infections. 
Therefore, the aim of this work was to design, synthesize and characterize new specific 
inhibitors against the WNV NS2B-NS3 protease. To achieve this objective, the 
following tasks should be performed: 
 Incorporation of decarboxylated P1 arginine mimetics in substrate-analogue 
inhibitor structures, a strategy, which was known from the development of 
highly potent inhibitors against trypsin like serine proteases and proprotein 
convertases. 
 Variation and optimization of the P2 and P3 residues by incorporation of various 
basic or hydrophobic amino acids. 
 Optimization of the P4 residue using a constant P3-P1 Lys-Lys-agmatine 
segment. 
 Combination of the most suitable P4, P3, P2 and P1 residues. 
 The inhibitory potency against the WNV NS2B-NS3-protease should be 
determined by an enzyme kinetic assay. For this purpose, a suitable fluorescence 
substrate should be developed. The specificity of selected derivatives should be 
tested with various trypsin like serine proteases. 
 Appropriate inhibitors should be provided for crystal structure analysis in 
complex with the WNV protease. 
 The information from crystal structure analysis should be used for further 
inhibitor optimization, e.g., for the development of cyclic inhibitors. 
 All of these inhibitors should be prepared by a combination of solution and solid 
phase peptide synthesis (SPPS). 
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3 Results and discussion  
3.1 Inhibitors containing decarboxylated P1 arginine mimetics 
In previous HTS studies it was shown that multiple positively charged compounds like 
guanylhydrazones inhibit the WNV protease with moderate Ki values.
67
 Therefore, 
similar multibasic inhibitors, which were originally synthesized in our laboratories for 
inhibiting furin,
75, 78
 were initially screened with the WNV protease. 
In our assay, the guanylydrazones 9 and 115
78
 possess a moderate affinity against the 
WNV protease (Ki ~ 30 μM, Table 3.1), whereby a further increase in potency was 
determined for compound 116 (Ki = 1.7 μM) containing four guanylhydrazone groups, 
which confirms the known preference of the WNV protease for multibasic substrates 
and inhibitors.
64
  
Substrate-analogue inhibitors containing the decarboxylated P1 arginine mimetic 
4-amidinobenzylamid or related analogues have been used for a long time to inhibit the 
trypsin-like serine protease thrombin,
70
 urokinase,
71
 factor Xa,
72
 factor VIIa,
73
 
plasmin,
74
 and the proprotein convertase furin.
75, 79
 Some of the multibasic 4-
amidinobenzylamide-derived furin inhibitors such as compounds 117 and 118, also 
reveal a moderate inhibition of the WNV protease with Ki values of 35 and 5.7 µM, 
respectively. Deletion of the P3 valine and replacement of both arginines with lysine 
residues of compound 117 led to a slightly improved potency against the WNV protease 
(37, Ki = 11.5 μM) and a reduced furin affinity. 
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Table 3.1: Screening of previously synthesized multibasic furin inhibitors
75, 78, 79
 with WNV protease.  
No. Structure 
Ki (μM) 
WNV Furin 
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NH
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a
 1.5 
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37 (MI-0324) 
H
N
N
H
O
O
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N
O
NH2
NH
NH2
NH2  
11.5 14.5 
a
 a Ki of 35 μM was previously described in literature for this compound.
67
 
The determined Ki values shown in Table 3.1 revealed that the 4-amidinobenzylamide is 
less suitable as P1 residue in WNV protease inhibitors. To enhance the potency of these 
substrate-analogue inhibitors, the 4-amidinobenzylamide was replaced by other 
decarboxylated arginine mimetics (Table 3.2). However, during the course of our work, 
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substrate analogue agmatine derivatives were already published as WNV protease 
inhibitors by Lim and coworkers.
69
 The most potent analogue of Lim′s first inhibitor 
series, 2-(biphenyl)acetyl-Lys-Lys-agmatine, inhibits the WNV protease with a Ki value 
of 2 μM. This compound was resynthesized in our laboratory as reference, whereby a 
similar inhibition constant of 1.8 μM against the WNV protease was determined under 
our assay conditions. 
Table 3.2: Inhibition of WNV protease by substrate analogue inhibitors with the general formula Phac-
Lys-Lys-P1. 
No. P1 Ki (μM) 
23 (MI-0631) 
H
N NH2  
134 
24 (MI-0638) 
H
N
H
N NH2
NH
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16 
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H
N
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H
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35 (MI-0641) H
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52 
36 (MI-0644) HN
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37 (MI-0324) 
H
N
NH
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11.5 
38 (MI-0645) H
N
NH2
  
84 
39 (MI-0646) H
N
H
N NH2
NH
  
1.2 
In this series, the P1 residue was modified keeping Phac-Lys-Lys as a constant P4–P2 
segment derived from inhibitor 37, which was also previously used in tripeptidic arginal 
inhibitors.
66
 Among derivatives 23–28 possessing a linear P1 residue, the highest 
potency with Ki = 3.9 μM was found for the agmatine analogue 26 (Table 3.2). This 
confirms previous results from a related series containing a slightly different P4 
residue.
69
 However, we found only a twofold decrease in potency for the homoagmatine 
derivative 28, which was > 20-fold less active in the previous work.
69
 In general, all 
compounds containing a primary amino group at the P1 position are less active than 
their guanidino analogues. No improvement was observed for derivatives 29–37 
containing more rigid aromatic P1 residues. As already described above, the 4-
amidinobenzylamide inhibitor 37 has relatively a poor affinity against the WNV 
protease, although it is an excellent P1 residue in inhibitors targeting serine proteases of 
families S1 and S8.
75
 This might be explained by the significant structural differences 
between their S1 pockets. The S1 pocket of the WNV protease, which belongs to the 
serine protease family S7, is shallower and partially solvent exposed relative to that of 
the trypsin- and furin-like serine proteases, both of which possess a deeply buried S1 
site perfectly suited for efficient binding of a benzamidine group. Negligible activity 
was determined for inhibitor 38 containing trans-4-amidomethylcyclohexylamine, 
although this P1 group is well suited for the design of thrombin inhibitors.
80, 81
 
However, its conversion into a guanidine residue in analogue 39 provided the most 
potent inhibitor of this series, possessing a Ki value of 1.2 μM. 
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Synthesis of inhibitors listed in Table 3.2 
For the preparation of these analogues, a solid-phase approach on acid-sensitive trityl 
chloride resin was used, as previously described for the synthesis of furin inhibitors.
75
 
Scheme 3.1 shows the synthetic strategy for all inhibitors containing a symmetric 
diamine moiety at the P1 position. Conversion of the C-terminal free amino group of the 
side-chain-protected intermediates with 1H-pyrazole-1-carboxamidine  HCl provided 
the corresponding guanidines after final deprotection. The same strategy was used for 
the synthesis of inhibitors 29–32; however, in that case, the synthesis was started by 
loading the trityl chloride resin with para- and meta-aminomethylbenzylamine. 
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Scheme 3.1. Synthesis of inhibitors 23–28. Reagents and conditions: a) Loading of the trityl chloride 
resin, 4 equiv diamine in dry DCM, 2 h, RT; b) standard Fmoc-SPPS, single couplings with 4 equiv 
amino acid (or phenylacetic acid), HOBt and HBTU, respectively, and 8 equiv DIPEA, 2 h, RT; c) 
TFA/TIS/H2O (95:2.5:2.5, v/v/v), 2 × 20 min; d) 3 equiv 1H-pyrazole-1-carboxamidine  HCl, 4 equiv 
DIPEA in DMF, 16 h; e) 32% HBr/AcOH, 1 h, RT, preparative HPLC. 
Inhibitors 33 and 34 were prepared according to Scheme 3.2, starting with loading of 
the protected P2 residue onto the 2-chlorotrityl chloride resin. The analogous 
compounds 35 and 36 and the benzamidine derivative 37 were synthesized by an 
identical strategy, using 3-(aminomethyl)aniline or 4-(aminomethyl)benzamidine
75
 
instead of 4-(aminomethyl)aniline for coupling to the intermediate Phac-Lys(Cbz)-
Lys(Cbz)-OH. For the synthesis of inhibitors 38 and 39, the intermediate trans-(4-
Fmoc-aminomethyl)cyclohexylamine (17) was prepared by starting from trans-N-(4-
tert-butoxycarbonylamino)cyclohexylmethylamine.
80
 Intermediate 17 was used for 
loading of the trityl chloride resin. The inhibitors 38 and 39 were further synthesized 
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according to Scheme 3.1, whereby N,N’-di-Boc-1H-pyrazole-1-carboxamidine was used 
for the conversion of the C-terminal amino group into a Boc-protected guanidine.  
d
c
Lys(Cbz) Lys(Cbz) OPhac
ClFmoc Lys(Cbz) OH +
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a
b
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NH
2
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Scheme 3.2: Synthesis of inhibitors 33-34. (a) Loading of 2-chlorotrityl chloride resin, Fmoc-Lys(Cbz)-
OH, 4 equiv DIPEA, dry DCM, 2h; (b) Fmoc SPPS (see Scheme 3.1); (c) 
TFA/TIS/H2O (95/2.5/2.5, v/v/v), 220 min; (d) 1 equiv 4-(aminomethyl)aniline, 1 equiv PyBOP, 1 equiv 
DIPEA, DMF; (f) 2 equiv N,N’-di-Boc-1H-pyrazole-1-carboxamidine, 4 equiv DIPEA in DMF, 16 h; (e) 
HBr/ acetic acid, 1h, preparative HPLC. 
3.2 Modification of P2 and P3 residues 
The results of the first inhibitor series revealed a preference of the WNV protease for 
the GCMA residue in P1 position (Table 3.2). Therefore, an attempt to replace lysine at 
P2, P3 or both of them with bigger and more rigid basic residues was performed, 
whereby the P1 GCMA- and P4 phenylacetyl-residue were maintained (Table 3.3). 
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Table 3.3: Inhibition of WNV protease by inhibitors with the general formula Phac-P3-P2-GCMA. 
No. P3 P2 Ki (μM) 
40 (MI-0648) Phe(4-AMe) Lys 4.7 
41 (MI-0649) Lys Phe(4-AMe) 29 
42 (MI-0647) Phe(4-AMe) Phe(4-AMe) 13.6 
43 (MI-0656) Phe(3-AMe) Lys 22.2 
44 (MI-0653) Lys Phe(3-AMe) 134 
45 (MI-0655) Phe(3-AMe) Phe(3-AMe) 44 
46 (MI-0651) Phe(4-GMe) Lys 43 
47 (MI-0650) Lys Phe(4-GMe) 76 
48 (MI-0652) Phe(4-GMe) Phe(4-GMe) 85 
49 (MI-0657) Phe(3-GMe) Lys 30 
50 (MI-0654) Lys Phe(3-GMe) 99 
51 (MI-0658) Phe(3-GMe) Phe(3-GMe) 21.5 
52 (MI-0659) Lys Phe(4-Gua) 18.2 
53 (MI-0660) Phe(4-Gua) Lys 29.8 
All inhibitors listed in Table 3.3 have reduced potency compared with the reference 
compound 39. Among them, the best Ki value was found for Phac-Phe(4-AMe)-Lys-
GCMA 40 with a 4 fold reduced potency of 4.7 μM. Furthermore, the conversion of the 
free amino group at the P3 side chain of inhibitor 40 into guanidine (compound 46) is 
not accepted and results in a 10-fold weaker WNV protease inhibition (Ki > 40 µM).  
The P2 and P3 residues in the derivatives 40 and 46 were reversed to obtain analogues 
41 and 47, however, this modification led to a dramatic loss of potency. These results 
raise the assumption that the S2 pocket of the WNV protease is too small to 
accommodate the more bulky substituted phenylalanines, and is only accepting the 
flexible lysine in P2 position. Additional replacement of the P2 and P3 lysine residues 
by Phe(4-AMe) led also to a nearly 13-fold reduced inhibitory potency (inhibitor 42). 
Further deterioration was found after the guanylation of the Phe(4-AMe) side chain at 
P2 and P3 in compound 48. 
Additional analogues 43-45 and 49-51 were prepared using the meta-substituted 
phenylalanine derivatives Phe(3-AMe) and Phe(3-GMe). The Ki values of these 
inhibitors are summarized in Table 3.3, however, all of them have a poor affinity 
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against the WNV protease (Ki > 20 µM). Two additional inhibitors 52 and 53 were 
prepared using para- guanylated phenylalanine in P2 or P3 positions, whereby they also 
possess poor potency (Ki values 18 and 30 µM, respectively). All of these data reveal 
that lysine is the most suitable P2 and P3 residues in substrate-analogue WNV protease 
inhibitors known so far.  
Synthesis of inhibitors listed in Table 3.3 
Inhibitors 40 and 46 were prepared according to Scheme 3.3, starting with the loading 
of the protected P2 residue onto the 2-chlorotrityl chloride resin. After mild acidic 
cleavage the side chain protected intermediate Phac-P3-P2-OH was coupled to the 
commercially available benzyl (1r,4r)-4-(aminomethyl)cyclohexylcarbamate (AMCA-
Cbz) in solution, followed by Cbz-deprotection by hydrogenation. The half amount of 
the obtained intermediate was guanylated using 1H-pyrazole-1-carboxamidine  HCl. 
Afterwards, this intermediate was completely deprotected to reveal inhibitor 40. The 
rest amount of the intermediate after the hydrogenation step was Tfa-deprotected, 
further guanylated and finally Boc-deprotected to obtain the inhibitor 46 (Scheme 3.3).  
The compounds 41-45 and 47-51 were synthesized in analogy to inhibitors 40 and 46, 
whereby the protected N,N’-di-Boc-1H-pyrazole-1-carboxamidine was used in the 
guanylation step (f) for the synthesis of inhibitors 45, 49 and 50 (not shown in Scheme 
3.3). 
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Scheme 3.3: Synthesis of inhibitors 40 and 46. (a) Loading of 2-chlorotrityl chloride resin, Fmoc-
Lys(Boc)-OH, 4 equiv DIPEA, dry DCM, 2h; (b) Fmoc SPPS (see Scheme 3.1); (c) 1% TFA in DCM, 
330 min; (d) 1 equiv benzyl (1r,4r)-4-(aminomethyl)cyclohexylcarbamate, 1 equiv PyBOP, 1 equiv 
DIPEA, DMF; (e) H2 and Pd/C as catalyst in 90% HAc, stirring overnight at RT (f) 3-6 equiv 1H-
pyrazole-1-carboxamidine  HCl, 4 equiv DIPEA in DMF, 16 h; (g) 1 N NaOH in dioxane/water, pH 12 
at RT 3 h, neutralization by 10% TFA; (h) 90% TFA, at RT 1 h, preparative HPLC. 
Inhibitor 53 was synthesized according to Scheme 3.4, starting with the loading of the 
protected P2 residue onto the 2-chlorotrityl chloride resin. The intermediate Phac-P3-
P2-OH was coupled to the commercially available AMCA-Cbz in solution, followed by 
hydrogenation (step e) to remove the Cbz-protection and to reduce the nitro into amino 
group. 
The free amino groups at the P1 residue and P3 side chain were converted into 
guanidine using N,N’-di-Boc-1H-pyrazole-1-carboxamidine (step f), followed by Boc-
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deprotection to obtain inhibitor 53. Compound 52 was prepared using the same strategy, 
whereby the P2 and P3 residues were reversed. 
c
Phe(4-NO2) Lys(Boc) OPhac
ClFmoc Lys(Boc) OH +
Fmoc Lys(Boc) O
a
b
Phe(4-NO2) Lys(Boc) OHPhac
Phe(4-NO2) Lys(Boc)
H
NPhac
HN Cbz
Phe(4-NH2) Lys(Boc)
H
NPhac
NH2
Phe(4-Gua(Boc)2) Lys(Boc)
H
NPhac
HN
HN
N
Phe(4-Gua) Lys
H
NPhac
HN
NH
2
NH
f
d
g
e
53
Boc
Boc
 
Scheme 3.4: Synthesis of inhibitor 53. (a) Loading of 2-chlorotrityl chloride resin, Fmoc-Lys(Boc)-OH, 4 
equiv DIPEA, dry DCM, 2h; (b) Fmoc SPPS (see Scheme 3.1); (c) 1% TFA in DCM, 330 min; (d) 1 
equiv benzyl (1r,4r)-4-(aminomethyl)cyclohexylcarbamate, 1 equiv PyBOP, 1 equiv DIPEA, DMF; (e) 
H2 and Pd/C as catalyst in 90% HAc, stirring overnight at RT (f) 2 equiv N,N’-di-Boc-1H-pyrazole-1-
carboxamidine, 4 equiv DIPEA in DMF, 16 h; (g) TFA, at RT 1 h, preparative HPLC. 
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3.3 Modification of P4 residue 
In an additional series, a search for more suitable P4 residues was performed, whereas 
Lys-Lys-agmatine was maintained as a constant P3–P1 segment, based on previous 
studies.
66
 In most cases ring-substituted phenylacetyl moieties were incorporated, and in 
two inhibitors an N-terminal Fmoc- or p-hyroxyphenyl-propionyl group was used 
(Table 3.4). Compared with the reference inhibitor 26 (phenylacetyl-Lys-Lys-agmatine, 
Ki = 3.9 µM), a twofold improvement in affinity was observed for the 4-phenyl-
phenylacetyl analogue 56. This tendency was also observed in the previously described 
arginal series.
66
 A similar activity was also found for most other analogues, whereby the 
lowest Ki values were determined for the dichloro-substituted inhibitors 73–75. 
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Table 3.4: Inhibition constants of the WNV protease by inhibitors with the general formula P4-Lys-Lys-
agmatine. 
No. P4 
Ki 
(μM) 
 
No. P4 
Ki 
(μM) 
54 
(MI-0662) 
O
O
*
 
11.2 
 
65  
(MI-0677) F
O
*  
1.1 
55 
(MI-0666) 
HO
*
O
 
17.8 
 
66  
(MI-0681) 
O
*
F  
1.35 
56  
(MI-0661) 
*
O
 
1.7 
 
67  
(MI-0675) 
F3C
O
*
 
1.0 
57  
(MI-0668) 
*
O
 
0.82 
 
68 
(MI-0670) 
Br
O
*  
1.15 
58  
(MI-0665) 
H3C
*
O
 
1.5 
 69 
(MI-0671) 
Br
O
*  
0.9 
59  
(MI-0664) 
CH3
*
O
 
1.5 
 
70  
(MI-0672) 
Cl
O
* 
2.0 
60  
(MI-0676) 
O
O
*  
0.83 
 
71 
(MI-0682) Cl
O
* 
0.76 
61  
(MI-0674) 
H3CO
O
*  
1.5 
 
72 
(MI-0678) 
Cl
O
*  
0.7 
62  
(MI-0667) 
HO
O
*  
0.93 
 73  
(MI-0680) 
ClCl
O
* 
0.6 
63  
(MI-0669) 
O2N
O
*  
1.15 
 74 
(MI-0663) 
Cl
Cl
O
* 
0.4 
64  
(MI-0673) 
F
O
*  
2.5 
 
75  
(MI-0679) 
Cl
Cl
O
*  
0.45 
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Derivatives 54–75 were prepared as described for inhibitor 26 in Scheme 3.1 using 
commercially available P4 acyl residues.  
3.4 Combination of the best P4 and P1 residues 
In the previous series, the strongest WNV protease inhibition was found for the P4 
dichloro-substituted inhibitors 73–75 and compound 39 containing the GCMA residue 
in P1 position. Therefore, both moieties were combined providing analogues 76–78, 
which are the most potent inhibitors of the WNV protease with Ki values < 0.15 µM 
(Table 3.5). These inhibitors were synthesized in analogy to the synthesis of 39. 
Table 3.5: Inhibition constants of the WNV protease with by inhibitors with the general formula P4-Lys-
Lys-GCMA 
P4
H
N
NH2
N
H
O
H
N
O
H
N NH2
NH
NH
2
 
No. P4 Ki (μM) 
76 (MI-0685) 
ClCl
O
* 
0.14 
77 (MI-0683) 
Cl
Cl
O
* 
0.13 
78 (MI-0684) 
Cl
Cl
O
*  
0.12 
3.5 Selectivity studies 
Some inhibitors were exemplarily tested against three trypsin-like serine proteases. 
Thrombin and factor Xa (fXa) are important enzymes in the blood coagulation cascade, 
and their inhibition could lead to bleeding complications. Matriptase belongs to the type 
II transmembrane serine proteases (TTSPs).
82
 It is involved in the terminal 
differentiation of the oral epithelium and the epidermis, and is critical for hair follicle 
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growth, but also emerged as a potential target for anticancer drugs.
83
 The results of 
these selectivity studies are summarized in Table 3.6. Both agmatine derivatives 56 and 
73 inhibit also matriptase in the low micromolar range, whereas the selected GCMA 
analogues 76-78 possess an improved selectivity with negligible affinity against the 
tested trypsin-like serine proteases. 
Table 3.6: Inhibition of the WNV and trypsin-like serine proteases by selected inhibitors. 
No. 
Ki μM 
matriptase  fXa
(a)
 thrombin
(a)
 WNV 
56 (MI-0661) 1.8 >200 >500 1.7 
73 (MI-0680) 5.2 >200 >500 0.6 
76 (MI-0680) 93 >200 >500 0.14 
77 (MI-0663) 84 >200 >500 0.13 
78 (MI-0679) 102 >200 >500 0.12 
(a)
Due to poor inhibitory potency, the provided data were calculated only from pre-assays using a single 
substrate concentration of 180 µM; these assays were performed with the substrates CH3OCO-dCha-Gly-
Arg-pNA (Km=105 µM) and CH3SO2-dCha-Gly-Arg-pNA (Km=40 µM) for fXa and thrombin, 
respectively. 
3.6 Stability test with trypsin 
Since these inhibitors contain additional basic residues in P2 and P3 position, they could 
be potential substrates of trypsin-like serine proteases. Therefore, inhibitor 76 (2,4-
dichloro-Phac-Lys-Lys-GCMA) was incubated with the nonspecific protease trypsin in 
tris buffer at pH 8.0 over a period of one hour, followed by HPLC analysis of the 
remaining inhibitor (detection at 220 nm, data not shown). Under the used condition 
approximately 8 % of inhibitor 76 was cleaved. The newly formed product elutes at 
30.8 min on HPLC (start at 1% solvent B), suggesting a cleavage after the P3 lysine, 
because its retention time is identical with that of 2,4-dichloro-Phac-Lys-OH, which 
was synthesized as reference. In contrast, no cleavage could be observed after the P2 
lysine, because the reference 2,4-dichlorophenylacetyl-Lys-Lys-OH is more hydrophilic 
and elutes at 25.95 min. Moreover, under identical conditions approximately 42% of the 
known chromogenic trypsin substrate methylsulfonyl-D-cyclohyexylalanine-Gly-Arg-p-
nitroanilide
84
 was hydrolyzed after the P1-Arg residue.  
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3.7 Structure of the WNV NS2B-NS3 protease in complex with inhibitor 
77
[1]
 
A crystal structure of the WNV NS2B-NS3 protease was solved in complex with one of 
the most potent inhibitors (3,4-dichlorophenylacetyl-Lys-Lys-GCMA) 77 (resolution 
3.2 Å, refined to a crystallographic R factor of 18.8%, Rfree=20.7 %). Despite the limited 
resolution, the electron density maps were clear and easily interpretable in most regions. 
At the N terminus of the NS2B chain (molecule A), electron density was visible for 
residues Ser47, His48, and Met49, which remained from the N-terminal His tag after 
cleavage by thrombin. The first authentic residue of NS2B is Thr50. At the C terminus 
of NS2B, the last residue defined by electron density was Pro91, leaving the five C-
terminal residues of NS2B and all nine residues of the artificial Gly4-Ser-Gly4 linker 
between the NS2B and NS3 (molecule B) chains without interpretable density. Beyond 
this linker, the first amino acid residue of NS3 also lacked meaningful electron density. 
At the C terminus of the NS3 chain, all residues were well defined by electron density 
except the very C-terminal Arg170. Although all other residues of the enzyme were 
included in the structural model, a number of individual side chains (Met49 of molecule 
A (Met49/A), Asp65/A, Glu67/A, Arg78/A, and Asp6 of molecule B (Asp6/B), 
Lys11/B, Glu12/B, Lys88/B, Lys117/B, Glu120/B, Lys142/B) lacked well-defined 
electron density. The corresponding atoms were refined with occupancy of less than one 
or even assigned zero occupancy. For the side chains of Met88/A and Gln86/B, 
alternative conformations were modeled, each refined with an occupancy of 50 %. 
Owing to limitations in the resolution of the diffraction data, only seven water 
molecules and one chloride ion could be located in the electron density maps. Only one 
of these water molecules is located in the active site region, forming 2.5 Å hydrogen 
bonds to the carbonyl oxygen atom of Gly153 and to Oδ1 of Asn152. However, it does 
not interact with the inhibitor. In the crystals, the protease is in the closed conformation, 
with the NS2B chain wrapping around NS3, with two strands (residues 53–58 and 73–
                                                 
[1] The crystal structure of inhibitor 77 in complex with the WNV NS2B-NS3 protease has been solved by 
Caroline Haase in the group of Prof. Dr. Rolf Hilgenfeld (Institute of Biochemistry, University Lübeck). 
The text and figures of this chapter were provided by C. Haase and R. Hilgenfeld and are nearly identical 
as already published.
[90] 
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76) of NS2B contributing to two β-sheets formed by NS3. The C-terminal portion 
(residues 78–86) of NS2B forms a β-hairpin, which is involved in inhibitor binding. 
Catalytic site: With the protease being in the closed conformation, the catalytic triad 
consisting of Ser 135, His51 and Asp75 is in active state. There is a 3.0 Å interaction 
between the hydroxyl group of the serine and Nε2 of the histidine. The Nδ1 atom of the 
latter is involved in a 2.8Å hydrogen bond to Oδ2 of Asp75. The oxyanion hole, formed 
by the amides of Gly133, Thr134, and Ser135, is in a non-catalytic conformation and 
would require a flip of the Thr132–Gly133 peptide bond to adopt the catalytically 
competent conformation.  
Inhibitor binding: Figure 3.1a shows a stereo view of inhibitor 77 within the active site 
of the WNV protease, displayed with its solvent-accessible surface. Key interactions 
between the protease and the inhibitor are indicated in Figure 3.1b. 
P1 residue: The GCMA moiety of the inhibitor is inserted into the relatively shallow S1 
pocket of the protease. As the compound lacks a covalent interaction with the catalytic 
nucleophile of the protease, the carbon atom adjacent to the amide NH of the P1 residue 
is at a distance of 3.3 Å from Ser135 Oγ. The P1 amide NH is involved in a 2.9 Å 
hydrogen bond to the carbonyl oxygen atom of Gly151. The P1 cyclohexyl ring is in a 
chair conformation and makes van der Waals interactions with tyrosine residues 150 
and 161. The latter interaction possibly involves a C-H··· π hydrogen bond 85, 86of ~3.3 
Å length between a methylene carbon atom of the cyclohexyl ring and the aromatic 
plane. Interestingly, the other side of the cyclohexyl ring is shielded from bulk solvent 
by the aromatic P4 residue of the inhibitor at a distance of ~3.8 Å (see below). The 
terminal P1 guanidinium group interacts with the carboxylate of Asp129 through two 
hydrogen bonds (2.7 and 2.9 Å), whereas the third guanidinium nitrogen atom is 
involved in a 2.7 Å hydrogen bond to the P4 carbonyl oxygen. There is also a 3.1 Å salt 
bridge between the guanidinium moiety and the carboxylate of Glu55 of the NS2B 
chain of a neighboring protease molecule in the crystal lattice. 
P2 residue: The lysine P2 side chain is well embedded in the S2 pocket, which is lined 
by His51 of the catalytic site, Asn152 of molecule B, and Gly83 and Asn84 of NS2B. 
The terminal amino group of the lysine makes a 3.2 Å interaction with the carboxylate 
of Asp75 of the catalytic site.  
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P3 residue: The main-chain carbonyl oxygen atom of the P3 residue accepts a 2.8 Å 
hydrogen bond from the hydroxyl group of Tyr161 and a 2.9 Å hydrogen bond from the 
NH of Gly153. The terminal amino group of the lysine side chain donates a 2.8 Å 
hydrogen bond to the carbonyl oxygen of Phe85 of NS2B. Thus, the NS2B polypeptide 
contributes to the formation of the S3 pocket in the closed conformation of the enzyme. 
P4 residue: As mentioned above, the carbonyl oxygen of the 3,4-dichlorophenylacetyl 
moiety accepts a 2.7 Å hydrogen bond from one terminal Nω of the P1 guanidinium 
group. A similar interaction between the P4 carbonyl and the P1 guanidine was also 
found in the crystal structure of the WNV protease in complex with the arginal-derived 
inhibitor Naph-KKRH (3e90.pdb).
77
 This intramolecular interaction constrains the 
inhibitor into a closed, horseshoe-like conformation, thereby positioning the aromatic 
plane above the P1 cyclohexyl ring and shielding it from bulk solvent. The distances 
between the aromatic plane and the two adjacent methylene units of the cyclohexyl ring 
are 3.8 Å, indicative of possible CH···π interactions.85, 86 
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a) 
 
b) 
 
Figure 3.1: Complex of inhibitor 77 in the active site of the WNV protease (2yol.pdb). Hydrogen bonds 
are indicated as black dashed lines. a) Stereo view of the complex, whereby the protease is shown with its 
solvent-accessible surface colored by electrostatic potential: negative and positive potentials are shown in 
red and blue, respectively. The residues of the catalytic triad are labeled. The 2 Fo-Fc electron density 
maps, contoured at a level of 1.1, are only shown for the inhibitor; its carbon atoms are shown in yellow, 
oxygen in red, nitrogen in blue, and chlorine in green. b) Key interactions observed in the complex, as 
discussed in the text. The carbon atoms of the protease and inhibitor are shown in grey and yellow, 
respectively. 
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The obtained crystal structure of inhibitor 77 in complex with the WNV NS2B-NS3 
protease encouraged us to perform further modifications within this substrate-analogue 
inhibitor type. These modifications are described in the following chapters. 
3.8 Second modification of P2 and P3 residues 
The initial modification of the P2 and P3 Lys residues with basic substituted 
phenylalanine analogues has only provided inhibitors with reduced potency (see Table 
3.3 in chapter 3.2). On the other side, the crystal structure of inhibitor 77 in complex 
with the viral NS2B-NS3 protease suggested that there is some empty space left in the 
S2 and S3 pockets and it might be possible to replace both lysines by other bulky basic 
or hydrophobic residues. 
Therefore, additional amino acids like norarginine (norArg), arginine, homo-2-
pyridylalanine (hAla(2-Pyr)) or bulky uncharged residues like phenylalanine and serine-
benzylether (Ser(Bzl)) were incorporated in a new inhibitor series with C-terminal 
agmatine (Table 3.7). 
Table 3.7: Inhibition of the WNV-NS2B-NS3 protease by inhibitors of the formula 3,4-
dichlorophenylacetyl-P3-P2-agmatine. 
No. P3 P2 Ki (μM) 
74 (MI-0663) Lys Lys 0.40 
79 (MI-0686) Lys norArg 0.85 
80 (MI-0687) norArg Lys 6.5 
81 (MI-0693) Lys Arg 9 
82 (MI-0694) Arg Arg 15.8 
83 (MI-0691) Lys hPhe 29.5 
84 (MI-0692) hPhe Lys 8.5 
85 (MI-0697) Lys Ser(Bzl) 97.6 
86 (MI-0698) Ser(Bzl) Lys 10.2 
87 (MI-0699) Lys D/L-hAla(2-Pyr) >500 
88 (MI-0731) D/L-hAla(2-Pyr) Lys 28.3 
Compared to inhibitor 74 the replacement of the lysine residues at P2 or P3 positions by 
norargine in inhibitors 79 and 80 led to about 2- or more than 10 fold reduced inhibitory 
potency, respectively. A strong drop in affinity was also observed after incorporation of 
arginine in P2 position (derivative 81, Ki value of 9 µM), whereby the replacement of 
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both lysines at P2 and P3 further reduced the potency (compound 82, Ki value of 
16 µM). A significantly weaker potency was also observed after replacement of the P2 
and P3 lysine residues with more bulky amino acids such as hPhe, Ser(Bzl) or 
D/L-hAls(2-Pyr).  
So far, the results from Tables 3.3 and 3.7 clearly reveal that all attempts to replace the 
lysine in P2 or P3 position were not successful and provided only compounds with 
relatively poor inhibitory potency against the WNV protease. Similar results have been 
published by other groups
66, 87
  
Synthesis of inhibitors 79-88 
Inhibitors 81-88 were prepared as described for inhibitor 26 in Scheme 3.1. A slightly 
modified strategy was used for the synthesis of compound 79. This inhibitor was 
prepared using Fmoc-Dab(Boc)-OH to generate the norArg at P2 after guanylation as 
shown in Scheme 3.5. Inhibitor 80 was also synthesized according to the same strategy, 
whereby the P2 and P3 residues were reversed. 
Lys(Cbz) Dab(Boc)
Cl+NH2
c
a
b
d
3,4-dichloro-Phac
(CH2)4H2N
H
N(CH2)4H2N
H
N(CH2)4
H
N
Lys(Cbz) Dab3,4-dichloro-Phac NH2(CH2)4
H
NLys(Cbz) norArg3,4-dichloro-Phac
H
N(CH
2
)
4
H
N
Lys norArg3,4-dichloro-Phac
H
N(CH2)4
H
N
e
NH2
NH
NH2
NH
79
Scheme 3.5: Synthesis of inhibitors 79: Reagents and conditions: a) Loading of the trityl chloride resin, 4 
equiv diamine in dry DCM, 2 h, RT; b) standard Fmoc-SPPS, single couplings with 4 equiv amino acid (or 
phenylacetic acid), HOBt and HBTU, respectively, and 8 equiv DIPEA, 2 h, RT; c) TFA/TIS/H2O (95:2.5:2.5, v/v/v), 
2×20 min; d) 6 equiv 1H-pyrazole-1-carboxamidine × HCl, 4 equiv DIPEA in DMF, 16 h; e) 32% HBr/AcOH, 1 h, 
RT, preparative HPLC. 
3.9 Incorporation of alkylated GCMA residues in P1 position 
The crystal structure of inhibitor 77 in complex with WNV NS2B-NS3 protease 
revealed two intermolecular hydrogen bonds (2.7 and 2.9 Å) between the guanidinium 
group of the P1 GCMA residue and Asp129 in the S1 pocket.  The third nitrogen atom 
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of the guanidinium group makes a close intramolecular contact to the carbonyl oxygen 
of the P4 acyl group (2.7 Å). Moreover, this guanidinium nitrogen is approximately 4 Å 
away from the terminal C carbon of the Ile155 side chain (Figure 3.2.).  This suggested 
that an alkylation of the P1 guanidino group by a short methyl or ethyl group, which 
maintains its basic character, could make a beneficial hydrophobic interaction to Ile155 
without disturbing the intramolecular H-bond to the P4 carbonyl oxygen or influenccing 
the intermolecular salt bridge to Asp129. 
 
Figure 3.2: Interaction of the P1 guanidino group of inhibitor 77 with the S1 pocket of the WNV 
protease. 
Therefore, two inhibitors of the general formula 3,4-dichloro-Phac-Lys-Lys-P1 
containing such alkylated guanidinium groups were synthesized to proof this 
assumption. However, the determined Ki values revealed a strongly reduced inhibitory 
potency for both compounds (Table 3.8). 
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Table 3.8: Inhibition of the WNV NS2B-NS3 protease by inhibitors with the general formula 
H
N
N
H
H
N
H
N
O
O
O
NH2
NH2
Cl
Cl
H
N
NH
R
 
No. R Ki (μM) 
77 (MI-0683) H 0.13 
89 (MI-0734) methyl 7 
90 (MI-0733) ethyl 11 
Synthesis of alkylated P1-GCMA derivatives 
The synthesis of the inhibitors 89 and 90 was performed according to Scheme 3.6. The 
used guanylation reagents ethyl methylcarbamimidothioate hydroiodide 21 or ethyl 
ethylcarbamimidothioate hydroiodide 22
88
 were prepared from the appropriate alkylated 
thioureas by treatment with iodoethane and were used without further purification. The 
intermediate 3,4-dichloro-Phac-Lys(Boc)-Lys(Boc)-AMCA was prepared by standard 
Fmoc-SPPS using Fmoc-AMCA (17) for the initial loading of the 2-chloro-tritylchlorid 
resin. After mild acidic cleavage the subsequent guanylation using reagents 21 or 22 
was performed in solution. The final removal of the Boc groups provided inhibitors 89 
and 90, respectively.  
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H
N
N
H
H
N
NH2
O
O
O
NH
HN
Cl
Cl
Boc
Boc
H
N
N
H
H
N
H
N
O
O
O
NH
HN
Cl
Cl
Boc
Boc
H
N
N
H
H
N
H
N
O
O
O
NH2
NH2
Cl
Cl
R
89 (MI-0734), R= -CH3
90 (MI-0733), R= -CH2-CH3
N
H
NH2
S
a R = -CH3 (21)
R = -CH2-CH3 (22)
b
c
N NH2
R
S
CH3
I-
R
NH
HN
R
 
Scheme 3.6: Synthesis of inhibitors 89 and 90. Reagents and conditions: a) abs. EtOH, 3.5 h, 60°C.; b) 2 
equiv 21 or 22, 4 equiv DIPEA in DMF, 24 h at RT; c) 90% TFA, at RT 1 h, preparative HPLC. 
3.10 Design and synthesis of cyclic inhibitors 
Many cyclic peptides with a wide spectrum of biological activities have been isolated 
from natural sources, like the antibiotics cyclosporine or gramicidin S. Therefore, the 
cyclization of peptides has also become a promising strategy for drug design. A key 
benefit of this modification is the reduction in conformational freedom, which can result 
in higher receptor binding affinities. Frequently, extra conformational constraints are 
incorporated, such as D- and N-alkylated-amino acids, α,β-dehydro amino acids or α,α-
disubstituted amino acid residues.
89
 These modifications also enhance the stability of 
the peptides against proteolytic degradation. 
Based on the crystal structure of the WNV protease with inhibitor 77 various cyclic 
inhibitors have been designed. The structure showed the inhibitor 77 in a horseshoe-like 
conformation, thereby positioning the aromatic P4 plane above the P1 cyclohexyl ring 
and covering it from bulk solvent. The distances between the phenyl ring and the two 
adjacent methylene units of the cyclohexyl group are 3.8 Å, indicative of possible 
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CH···π interactions.90 It was also found that the distance between the meta chloro atom 
on the P4 phenyl ring and the carbon adjacent to the P1 amide NH is about 5.3 Å. This 
carbon should be located at a similar position as the putative Cα-atom of a P1 arginine 
in substrate-analogue structures. 
 
Figure 3.3: Inhibitor 77 in complex with the WNV NS2B-NS3 protease. The distance between the Cα 
atom of the P1 residue and the meta chloro atom at the P4 phenyl ring is approximately 5.3 Å. 
Therefore, we assumed that it should be possible to connect the P4 and P1 residues via a 
suitable P1' linker residue. However, with this strategy it could come to a simple 
proteolytic cleavage after the P1 residue, providing a product with a C-terminal 
carboxylate structure, which should be repelled by the nucleophilic side chain of the 
active site Ser135. There exist several strategies to enhance the stability of a peptide 
bond via modification of the P1' residue. One approach is the incorporation of N-
alkylated P1' residues, like sarcosine or proline. A P1' proline was successfully 
incorporated into the clinically used thrombin inhibitor hirulog-1 (bivalirudin, 
Angiomax

), compared to its glycine analogue it was approximately 1000-fold more 
stable against thrombin.
91
 An alternative strategy is the incorporation of P1' residues in 
D-configuration or of very bulky residues. 
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Therefore, before synthesizing the first cyclic inhibitors, several linear peptides have 
been prepared and their inhibition constants and proteolytic stability were analyzed 
(Table 3.9). 
Table 3.9: Inhibition of the WNV protease by linear peptides of the general formula P4-Lys-Lys-P1-R 
No. P4 P1 R Ki (µM) 
91 (MI-0751) Phac Arg Gly-Gly-NH2 0.8  
92 (MI-0737) Phac Arg Gly-NH2 2 
93 (MI-0740) Phac Arg Ala-NH2 25 
94 (MI-0741) Phac Arg Val-NH2 105 
95 (MI-0739) Phac Arg Tle-NH2 140 
96 (MI-0738) Phac Arg Pro-NH2 200 
97 (MI-0752) Phac Arg D-Ala-NH2 75 
98 (MI-0753) Phac Arg Sar-NH2 50 
99 (MI-0754) Phac Arg Gaba-NH2 15 
100 (MI-0755) Phac Arg Aca-NH2 17 
101 (MI-0756) Phac Arg NH2 0.4 
102 (MI-0742) 3,4-dichloro-phac Arg Gly-NH2 1.3 
103 (MI-0757) 3,4-dichloro-phac Arg NH2 0.39 
104 (MI-0763) Phac hArg NH2 1.9 
105 (MI-0762) 3,4-dichloro-phac hArg NH2 1.7 
The first peptide 91 contains a Gly-Gly-NH2 as P1'-P2' segment and inhibits the WNV 
protease with a Ki value of 0.8 µM. Elimination of the P2' residue resulted in slightly 
reduced potency, in contrast additional deletion of P1' Gly enhanced the affinity, a Ki 
value of 0.4 µM was determined for compound 101. 
Additional modifications of the P1' residue, like incorporation of N-alkylated amino 
acids (proline and sarcosin), of amino acids in D-configuration or several 
nonproteinogenic amino acids, dramatically reduced the potency of peptides 93–100. 
Moreover, peptides containing a P1 Arg-NH2 moiety could be also potential substrates 
of trypsin-like serine proteases, therefore additional inhibitors 104 and 105 containing a 
homoarginine amide were prepared, which should have an improved proteolytic 
stability (not tested so far). As expected, a relatively weak inhibition constant of 
27.1 µM was determined for the cleavage product Phac-Lys-Lys-Arg-OH with a free 
carboxylate structure in P1 position (MI-0764). 
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From the kinetic measurements, there was no hint that compound 91 was substantially 
cleaved as a substrate of the WNV protease during the 10 min assay time. The enzyme 
kinetic analysis revealed linear progress curves and normal Dixon plots typical for a 
reversible competitive inhibition mechanism. To further prove this result, this 
compound was also incubated with the WNV protease and at various time points 
samples were analyzed by HPLC (Figure 3.4). As reference, an identical concentration 
of the chromogenic substrate Phac-Lys-Lys-Arg-pNA 112 (MI-0744) containing the same 
P4-P1 segment was used, which provides a yellow color after cleavage. The HPLC 
analysis after 4 and 8 h incubation with peptide 91 (traces 3 and 4 in Figure 3.4b) 
revealed a minor formation of the cleavage product Phac-Lys-Lys-Arg-OH (elution at 
17.6 min, trace 5), whereas a significantly larger amount was detected after incubation 
with the pNA substrate 112 at the same time points (Figure 3.4a). The decrease of the 
peak areas for compound Phac-Lys-Lys-Arg-pNA (112) revealed that approximately 33 
% and 51 % were cleaved after 4 and 8 hours, respectively. In analogy, only 19 % of 
peptide 91 was cleaved after 8 h. It is well known that strong binding substrates with 
low Km values often suffer from poor kcat values and therefore, are considered as 
inhibitors. A similar situation was described for the thrombin inhibitor hirulog-1
91
 and 
the dipeptidyl peptidase IV inhibitors Diprotin A (H-Ile-Pro-Ile-OH) and B (H-Val-Pro-
Leu-OH )
92
, although all of them are simply poor substrates with low conversion rates. 
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a) 
 
b) 
 
c) 
 
Figure 3.4: HPLC analysis of peptides 91, 101 and 112 incubated with the WNV-protease. (a). Phac-Lys-
Lys-Arg-pNA (112, elution at 27,1 min) was incubated with the WNV protease and analysed by HPLC at 
0 (trace 1), 1 (trace 2), 4 (trace 3) and 8 hours (trace 4). The reference compound Phac-Lys-Lys-Arg-OH 
elutes at 17.6 min (trace 5) and p-nitroaniline at 29.3 min (broad peak in trace 6). (b). The peptide 
Phac-Lys-Lys-Arg-Gly-Gly-NH2 (91, elution at 16.4 min) was incubated with the WNV protease at 
0 (trace 1), 1 (trace 2), 4 (trace 3) and 8 (trace 4) hours. The reference compound Phac-Lys-Lys-Arg-OH 
is shown in trace 5, whereas the second cleavage product H-Gly-Gly-NH2 is not detectable to poor 
absorbance under this condition. (c) The peptide Phac-Lys-Lys-Arg-NH2 (101, elution at 16.7 min) was 
incubated with the WNV protease at 0 (trace 1), 1 (trace 2), 4 (trace 3) and 8 (trace 4) hours. The 
reference compound Phac-Lys-Lys-Arg-OH is shown in trace 5. 
Several other peptides (92, 99 and 100) were incubated with the WNV-protease under 
identical conditions. For all of these peptides no or negligible cleavage was observed 
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(data not shown). As an additional example the incubation of the best inhibitory peptide 
Phac-Lys-Lys-Arg-NH2 (101) with the WNV protease is shown in Figure 3.4c. Under 
the used conditions only a minor cleavage was observed. 
These results encouraged us to synthesize the cyclic inhibitors 106 and 107 (Figure 3.5) 
containing a P1' 4-aminobutanoic acid interconnected to the P4 2-(3-
aminophenyl)acetyl or 2-(3-(aminomethyl)phenyl)acetyl residues. However, only weak 
inhibition was observed for both compounds. Most likely, this P1' linker was too short 
to maintain the optimal backbone conformation of the inhibitor. 
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Figure 3.5: Structures and Ki values of cyclic inhibitors 106 and 107, including their linear analogues. 
An alternative cyclization without a P1' linker was performed by direct interconnection 
of the P1 side chain to the P4 group. To enable such a coupling a suitable functional 
group is needed in the P1 side chain. Therefore, lysine or ornithine residues in both 
configurations were coupled via their side chain amino function to the P2 residue and 
their -amino group was finally converted into guanidine, whereby the -carboxyl 
function can be used for cyclization (Figure 3.6). 
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Figure 3.6: The GCMA residue of inhibitor 77 as template for the design of a new P1 residue suitable for 
cyclization. 
According to this strategy, four inhibitors were synthesized using lysine or ornithine in 
D and L configuration (Table 3.10). 
Table 3.10: Inhibition of the WNV protease by cyclic peptides 108-111 of the general formula 
N
H
N
H
NH O
O
O
NH2
H2N
O
HN
H
N
*
n
NH2
NH  
No. n * Ki (µM) 
108 (MI-0758) 2 L 14.5 
109 (MI-0759) 2 D 26.4 
110 (MI-0760) 1 L 44.7 
111 (MI-0761) 1 D 49 
 
However, for all of these peptides only poor Ki values > 10 µM were determined. 
Therefore, these cyclic peptides are more than 25-fold weaker inhibitors than the linear 
peptide Phac-Lys-Lys-Arg-NH2 (101). The lysine-derived peptides are slightly better 
than the shorter ornithine-based compounds, however, their Ki values are very similar. 
Although these first results of the cylic peptides are discouraging, it might be possible to 
modify the interconnection between the P1 and P4 residues by insertion of suitable 
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linkers, which could provide more flexibility. Such compounds should be chemically 
well accessible, as seen from the used synthesis protocol described in the next 
paragraph. 
Synthesis of the linear peptides and cyclic inhibitors 
All peptides with a C-terminal amide function were synthesized by SPPS on Fmoc-
Rink-Amide resin using a standard Fmoc protocol. The peptides were cleaved from the 
resin using strong acidic conditions. 
The synthesis of the cyclic inhibitor 107 was performed according to Scheme 3.7. A 
solid-phase approach on acid-sensitive 2-chlorotrityl chloride resin was used for the 
preparation of the protected linear intermediate (steps a, b and c). A small amount of 
this intermediate was completely deprotected to reveal the linear peptide as reference 
(step e), where the residual amount was cyclized in solution to give the protected cyclic 
intermediate (step d). The final deprotection was performed using strong acidic 
conditions (step e) to reveal inhibitor 107 (Scheme 3.7). Peptide 106 was prepared by 
the same strategy, whereby a 3-NH2- Phac-residue was incorporated as P4 group. 
c
ClFmoc Gaba OH +
O
a
b
d
Fmoc Gaba
OGaba3-NH2-CH2-Phac-Lys(Boc)-Lys(Boc)-Arg(Pbf)-
3-NH2-CH2-Phac-Lys(Boc)-Lys(Boc)-Arg(Pbf )-Gaba-OH
3-NH-CH2-Phac-Lys(Boc)-Lys(Boc)-Arg(Pbf )-Gaba-
e
e
3-NH2-CH2-Phac-Lys-Lys-Arg-Gaba-OH
3-NH-CH2-Phac-Lys-Lys-Arg-Gaba-
107
107b
Scheme 3.7: Synthesis of inhibitor 107. (a) Loading of 2-chlorotrityl chloride resin, Fmoc-Gaba-OH, 4 
equiv DIPEA, dry DCM, 2 h; (b) Standard Fmoc SPPS (see Scheme 3.1); (c) 1% TFA in DCM, 330 
min; (d) 3 equiv Bop; 3-5 equiv DIPEA pH  8-9, DMF, ~ 72 h (e) TFA, at RT 1 h, preparative HPLC.  
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The critical step during the preparation of cylic peptides is normally the ring closure 
reaction, which is exemplarily shown for step d in Scheme 3.7. The HPLC 
chromatograms reveal a relatively clean cyclization reaction (Figure 3.7). 
 
Figure 3.7: HPLC analysis of the intermediates after step c and step d in Scheme 3.7 (start at 10% solvent 
B). 3-NH2-CH2-Phac-Lys(Boc)-Lys(Boc)-Arg(Pbf)-Gaba-OH is shown in black and elutes at 41.6 min 
(trace 1), whereas c[3-NH2-CH2-Phac-Lys(Boc)-Lys(Boc)-Arg(Pbf)-Gaba] is shown in blue and elutes at 
51.9 min (trace 2). 
 
The four cyclic inhibitors 108-111 were prepared as described in Scheme 3.8. The 2-
chlorotritylchlorid resin was loaded with the L- or D-derivatives of Boc-Lys(Fmoc)-OH 
or Boc-Orn(Fmoc)-OH. After removal of the Fmoc group in the side chain, the 
following residues were coupled by standard Fmoc SPPS (step b). After mild acidic 
cleavage of the peptide from resin (step c), the linear intermediates were cyclized in 
solution to give the Cbz- and Boc-protected cyclic peptides (step d). The Boc- 
protection was removed by TFA (step e), and the obtained free amine was converted 
into the bis-Boc-ptotected guanidine (step f). Final deprotection by HBr in acetic acid 
provided the cyclic peptides 108-109 (step g). 
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Scheme 3.8: Synthesis of inhibitors 108-111. (a) Loading of 2-chlorotrityl chloride resin with 1 equiv of 
the indicated amino acid derivative, 4 equiv DIPEA, dry DCM, 2 h; (b) Standard Fmoc SPPS (see 
Scheme 3.1); (c) 1% TFA in DCM, 330 min; (d) 3 equiv Bop; 3 equiv DIPEA, DMF, ~ 72 h; (e) 90% 
TFA, at RT 1 h; (f) 2 equiv N,N’-di-Boc-1H-pyrazole-1-carboxamidine, 4 equiv DIPEA in DMF, 16 h (g) 
32% HBr in acetic acid, 1h, preparative HPLC. 
The exemplarily shown HPLC chromatograms for the cyclization step d during the 
synthesis of compound 108 revealed also a relatively clean cyclization, which was 
similar for the other three intermediates (Figure 3.8). 
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Figure 3.8: HPLC analysis of the intermediates after step c (linear peptide in trace 1 shown in black, 
eluation at 39.6 min) and step d (cyclic peptide in trace 2 shown in blue, eluation at 50.9 min) during the 
synthesis of inhibitor 108 (Scheme 3.8). The HPLC runs started at 10% solvent B. 
3.11 Determination of inhibitory constants 
The Ki values of all inhibitors were determind using the fluorogenic substrate Phac-Leu-
Lys-Lys-Arg-AMC (114). This compound was derived from the widely used 
chromogenic substrate Ac-Leu-Lys-Lys-Arg-pNA
66
 with two modifications. The 
incorporation of a fluorogenic AMC group improves its sensitivity and enables the use 
of lower enzyme concentrations in the assay, while the N-terminal phenylacetyl residue 
is known to be a suitable P4 moiety based on various inhibitor studies.
66
 For the Ki 
determinations according to the method of Dixon three different substrate 
concentrations (200, 100 and 50 µM in the assay) were used. The Km and Vmax of 
substrate 114 were determined at pH 8.5 (Km= 47.5±1.7 µM, kcat= 0.26± 0.003 s
-1
, and 
kcat/Km = 5460 s
-1
M
-1
). The steady-state rates v were calculated from the linear progress 
curves. The Ki values were obtained from Dixon plots, as shown in Figure 3.9 for 
inhibitor 78, which has a Ki value of 0.12 µM. 
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Figure 3.9. Dixon plot of inhibitor 78. Kinetic measurements were performed with three different 
substrate concentrations (Phac-Leu-Lys-Lys-Arg-AMC:  50,  100, and  200 µM) in the presence of 
2 nM WNV NS2B-NS3 protease using various inhibitor concentrations. The dashed line represents 
1/Vmax, which was obtained from a Michaelis-Menten curve measured in parallel on the same 96-well 
plate. 
During the course of work and based on the preferred P4-P2 segment in substrate-
analogue inhibitors a second fluorogenic substrate Phac-Lys-Lys-Arg-AMC (113, MI-
0743) was prepared. For this substrate a Km of 12.16 µM and a kcat of 0.58 s
-1
 were 
determined, resulting in a kcat/Km value of 48,100
 
 s
-1
M
-1
, which is nearly 9 times higher 
than for substrate 114. 
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4 Conclusion  
Potent inhibitors of the West Nile virus NS2B-NS3 protease could be useful drugs for 
the treatment of WNV infections. Therefore, in the present work, new substrate 
analogue inhibitors against the WNV protease have been developed. 
Inhibitors with decarboxylated P1 arginine mimetics 
In the first series, new inhibitors containing various decarboxylated arginine mimetics 
in P1 position have been synthesized and characterized. Most of these arginine mimetics 
were incorporated in form of their amine precursors, which were finally converted into 
the corresponding guanidine analogues. In all cases the P1 guanidine inhibitors were 
more potent than their amine analogues. Moreover, most of the inhibitors with aliphatic 
P1 moieties showed higher potency than analogues containing aromatic P1 groups. In 
this series the cyclic trans-(4-guanidino)cyclohexylmethylamide (GCMA) was 
identified as the most suitable P1 residue. The strongest inhibitory potency was 
determined for compound Phac-Lys-Lys-GCMA (39) possessing an inhibition constant 
of 1.2 μM. The best analogue containing a linear P1 residue Phac-Lys-Lys-agmatine 
(26) was identified, which inhibits the WNV protease with a Ki value of 3.9 μM. 
Modification of P2 and P3 residues 
It was known from literature that lysine is the most suitable P2 and P3 residue among 
the proteinogenic amino acids, when incorporated in substrate analogue inhibitors 
against the WNV protease. However, the lysine sidechain in P2 and P3 position is very 
flexible, therefore it should be replaced by more rigid basic amino acids. Various amino 
or guanidino substituted phenylalanines were incorporated in a second inhibitor series, 
whereby the P1 GCMA and P4 phenylacetyl residues were maintained. However, all of 
these inhibitors have reduced inhibitory potency (Table 3.3).  
Modification of P4 residues 
In this series, a P3-P1 Lys-Lys-agmatine segment was maintained, whereby only the P4 
residue was modified. Based on the known preference of the WNV protease for 
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inhibitors with a P4 phenylacetyl group in most cases substituted phenylacetyl residues 
were incorporated. Surprisingly, all of the substituted phenylacetyl residues led to an 
improved potency, whereby the incorporation of a Fmoc- or p-hyroxyphenylpropionyl 
group led to dramatic loss in potency. The dichloro-substituted phenylacetyl moieties 
were found to be the most suitable P4 residues providing agmatine-derived inhibitors 
with Ki values of approximately 0.5 µM (Table 3.4). 
Combination of the best P4 and P1 residues 
From the previous series, the guanidine-substituted cyclohexylmethyl amide (GCMA) 
and the dichloro-substituted phenylacetyl moieties were found to be the most 
appropriate P1 and P4 residues. In contrast, no improvement was achieved by 
replacement of lysine in P2 or P3 position with other basic amino acids. Therefore, a 
combination of the different dichloro-substituted phenylacetyl residues in P4 position 
with the P1 GCMA residue provided further improved inhibitors with Ki values < 0.15 
µM (Table 3.5). 
Selectivity studies of selected inhibitors 
Selected inhibitors, including the three most potent inhibitors containing a P1 GCMA 
group and two additional agmatine derivatives, were tested against the three trypsin-like 
serine proteases thrombin, factor Xa and matriptase (Table 3.6). The agmatine 
derivatives 56 and 73 have shown a low micormolar inhibitory range against matriptase, 
whereas the selected GCMA analogues 76-78 possess an improved selectivity with 
negligible affinity against the tested trypsin-like serine proteases. 
X-ray stracture of the WNV NS2B-NS3 protease in complex with inhibitor 77 
In the group of Prof. Hilgenfeld (University Lübeck) a crystal structure of the WNV 
NS2B-NS3 protease in complex with compound 3,4-dichlorophenylacetyl-Lys-Lys-
GCMA (77) was solved, which is one of the most potent inhibitors. The inhibitor adopts 
a compact horseshoe-like conformation, whereby the P4 phenyl group comes in close 
contact to the P1 cyclohexyl ring. This conformation is stabilized by intramolecular 
hydrogen bond between the P4 carbonyl oxygen and the P1 guanidino group. 
Additionally, dobble salt bridges were observed between P1 guanidino group and the 
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Asp129 sidechain. These interactions explain the high potency of the inhibitors with P1 
trans-(4-guanidino)cyclohexylmethylamide residue. 
Modifications deduced from the crystal structure 
The obtained crystal structure revealed the binding of inhibitor 77 in the active site of 
the WNV NS2B-NS3 protease. The observed binding mode motivated us to perform 
further modifications within this substrate-analogue inhibitor type, the results are 
summarized in the following points: 
 The observed empty space left in the S2 and S3 pockets of the crystal structure 
suggested that it might be possible to replace both lysines by additional basic or 
more bulky hydrophobic residues. However, a relatively poor inhibitory potency 
was determined for all of these inhibitors (Table 3.7). Therefore, lysine is still 
the most suitable P2 and P3 residue in substrate-analogue inhibitors, so far. 
 The distance between the nitrogen atom of the GCMA guanidinium group and the 
side chain of Ile155 is about 4 Å. This suggested that an alkylation of the P1 
guanidine by a small alkyl group could provide an additional hydrophobic 
interaction in the extended S1 pocket. However, a reduced potency was found 
for these alkylated inhibitors (Table 3.8). 
 Inhibitor 77 adopts a horseshoe-like conformation, whereby the P4 phenyl ring 
comes in close contact to the P1 residue. This conformation encouraged us to 
prepare various cyclic analogues, which should possess a reduced flexibility 
compared to their linear analogues. In a first attempt, a head-to-tail cyclization 
using a P1' linker to interconnect the P1 with the P4 residue was performed. Due 
to a potential proteolytic cleavage after the P1 residue, a series of peptides 
containing various P1'-moieties were synthesized and tested for stability. 
Incubation of most of these peptides with the WNV protease revealed a 
relatively high stability against proteolytic degradation. For some of these 
analogues a relatively strong inhibitory potency was determined, e.g., Phac-Lys-
Lys-Arg-NH2 (101) inhibits the WNV protease with a Ki value of 0.4 µM 
according to a reversible competitive inhibition mechanism. In a second 
cyclization attempt a direct coupling between the P1 and P4 residues was 
performed. Therefore, the P4-P2 segment was bound to a side chain instead 
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amino group of a lysine or ornithine residue in P1 position. Their α-amino 
groups were converted into a guanidine, whereas their α-carboxyl moieties were 
coupled to the P4 residue. However, only a weak inhibition was determined for 
all of these cyclic compounds. 
In this present work, new decarboxylated arginine memtics inhibitors against the WNV 
NS2B-NS3 protease were developed. In comparison to the known agmatine derivatives, 
the P1 trans-4-Guanidinocyclohexylmethylamid containing inhibitors have higher 
potency and selectivity against the WNV. Moreover, the first crystal structure of the 
WNV protease in complex with small noncovalently-binding inhibitor was solved. 
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4 Zusammenfassung  
Wirksame Hemmstoffe der WNV NS2B-NS3-Protease könnten nützliche Wirkstoffe 
für die Behandlung von Erkrankungen nach WNV-Infektionen sein. Daher wurden in 
der vorliegenden Arbeit neue, substratanaloge Inhibitoren gegen die WNV-Protease 
entwickelt und charakterisiert. 
Inhibitoren mit decarboxylierten P1 Argininmimetika 
In einer ersten Serie wurden neue Inhibitoren mit verschiedenen decarboxylierten 
Argininmimetika in P1-Position synthetisiert und charakterisiert. Der Einbau dieser 
Argininmimetika erfolgte in der Regel in Form ihrer Aminvorstufen, welche 
anschließend in die entsprechenden Guanidinanaloga umgewandelt wurden. In allen 
Fällen waren die Hemmstoffe mit den Guanidinoresten in P1-Position wirksamer als 
ihre Aminanaloga. In der Regel waren die Verbindungen mit aliphatischen P1-Resten 
stärkere Inhibitoren als die Analoga mit aromatischen P1-Gruppen. Als besonders 
wirksames P1-Derivat innerhalb dieser Serie wurde der trans-4-
Guanidinocyclohexylmethylamid-Rest (GCMA) identifiziert. Die stärkste Hemm-
wirkung mit einem Ki-Wert von 1,2 µM wurde für die Verbindung Phac-Lys-Lys-
GCMA (39) bestimmt. Als wirksamstes Derivat mit einem linearen P1-Rest wurde der 
Inhibitor Phac-Lys-Lys-Agmatin (26) erhalten, das die WNV-Protease mit einer 
Hemmkonstanten von 3.9 µM inhibiert. 
Modifizierung der P2- und P3-Reste 
Aus der Literatur ist bekannt, dass Lysin die günstigste proteinogene Aminosäure für 
die P2- und P3-Position in substratanalogen Inhibitoren der WNV-Protease ist. Jedoch 
ist die Seitenkette des Lysins sehr flexibel. Deshalb wurde in einer weiteren Serie das 
Lysin in diesen beiden Positionen durch rigidere, basische Aminosäurereste ersetzt. 
Dabei wurden mit Amino- oder Guanidinogruppen substituierte Phenylalanine 
eingebaut, wobei der trans-4-Guanidinocyclohexylmethylamid-Rest in P1-Position und 
die P4-Phenylacetylgruppe beibehalten wurden. Jedoch wurde für alle Inhibitoren dieser 
Serie eine verringerte Hemmwirkung festgestellt (Tabelle 3.3). 
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Modifizierung des P4-Restes 
In diesem Falle wurde der Baustein Lys-Lys-Agmatin als P3-P1-Segment beibehalten 
und nur der P4-Rest modifiziert. Da aus der Literatur bereits bekannt war, dass die 
WNV-Protease eine Phenylacetylgruppe in P4-Position bevorzugt, wurden vor allem 
substituierte Phenylacetylreste verwendet. Überraschenderweise bewirkte der Einbau 
sämtlicher substituierten Phenylacetyl-Derivate eine Verstärkung der Hemmwirkung, 
im Gegensatz dazu kam es nach Ankopplung einer N-terminalen Fmoc – oder p-
Hydroxyphenylpropionylgruppe zu einem drastischen Aktivitätsverlust. Als besonders 
geeignet haben sich Phenylacetylreste in P4-Position erwiesen, die mit zwei 
Chloratomen substituiert sind. Jedoch wurde die Hemmwirkung durch das 
Substituierungsmuster am Phenylring kaum beeinflusst, für die drei wirksamsten 
Inhibitoren wurden Ki-Werte um 0,5 µM bestimmt (Tabelle 3.4). 
Kombination der wirksamsten P4- und P1-Reste 
Aus den zuvor untersuchten Inhibitorserien war bekannt, dass das trans-4-
Guanidinocyclohexylmethylamid und die dichlorsubstituierten Phenylacetylgruppen 
besonders geeignete P1- und P4-Reste sind. Im Gegensatz dazu führte der Austausch 
des Lysins in P2- und/oder P3-Position durch andere basische Aminosäuren zu einem 
deutlichen Aktivitätsverlust. Deshalb wurden neue Inhibitoren durch Kombination der 
besten P1- und P4-Reste synthetisiert, wobei die beiden Lysinreste in P2- und P3-
Position beibehalten wurden. Dadurch konnte die Hemmwirkung weiter verbessert 
werden und es wurden drei Inhibitoren mit Ki-Werten < 0.15 µM erhalten (Tabelle 3.5). 
Selektivitätsstudien ausgewählter Inhibitoren 
Für einige Inhibitoren, darunter die drei wirksamsten Verbindungen mit einem trans-4-
Guanidinocyclohexylmethylamid in P1-Position und zwei zusätzliche Agmatinderivate, 
wurde die Hemmwirkung auf die drei trypsinartigen Serinproteasen, Thrombin, Faktor 
Xa und Matriptase untersucht (Tabelle 3.6). Die Agmatinderivate 56 und 73 inhibieren 
neben der WNV-Protease auch Matriptase im niedrig-mikromolaren Bereich. Dagegen 
besitzen die ausgewählten Inhibitoren 76-78 mit einem trans-4-
Guanidinocyclohexylmethylamid eine höhere Selektivität und haben nur eine 
vernachlässigbare Hemmwirkung auf die untersuchten trypsinartigen Serinproteasen. 
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Struktur der WNV NS2B-NS3-Protease im Komplex mit Inhibitor 77 
Im Arbeitskreis Hilgenfeld (Universität Lübeck) wurde eine Kristallstruktur der WNV 
NS2B-NS3-Protease im Komplex mit der Verbindung 3,4-dichlorphenylacetyl-Lys-
Lys-trans-4-Guanidinocyclohexylmethylamid (77) gelöst. Der gebundene Inhibitor 
nimmt eine kompakte hufeisenförmige Konformation an, in der der P4 Phenylring in 
engen Kontakt mit dem Cyclohexylring des P1-Restes kommt. Diese Konformation 
wird durch eine intramolekulare Wasserstoffbrückenbindung zwischen dem P4 
Carbonylsauerstoff und der P1-Guanidinogruppe stabilisiert. Daneben wurde eine 
doppelte Salzbrücke der P1-Guanidinogruppe zur Seitenkette des Asp129 gefunden. 
Diese Wechselwirkungen erklären die starke Hemmwirkung der Inhibitoren mit einem 
trans-4-Guanidinocyclohexylmethylamid in P1-Position. 
Aus der Kristallstruktur abgeleitete Modifizierungen 
Aufgrund des beobachteten Bindungsmodus des Inhibitors 77 im aktiven Zentrum der 
WNV NS2B-NS3-Protease wurden die substratanalogen Inhibtoren weiter modifiziert, 
die Ergebnisse sind in den folgenden Punkten zusammengefasst. 
 Da in der Kristallstruktur beobachtete wurde, dass die S2- und S3-Taschen 
durch die Lysinseitenketten nicht vollständig ausgefüllt sind, wurden die Lysine 
durch andere basische oder sterisch anspruchsvollere und hydrophobe 
Aminosäurereste ersetzt. Es wurde jedoch für all diese Inhibitoren nur eine 
schwache Hemmwirkung bestimmt. (Tabelle 3.7). Nach derzeitigem 
Erkenntnisstand ist Lysin der bevorzugte P2- und P3-Rest in substratanalogen 
Inhibitoren der WNV-Protease. 
 Die Distanz zwischen dem Stickstoffatom der Guanidinogruppen des trans-4-
Guanidinocyclohexylmethylamid und der Seitenkette des Ile155 beträgt etwa 
4 Å. Deshalb wurde das P1-Guanidin mit einer Methyl- oder Ethylgruppe 
alkyliert, um eine zusätzliche hydrophobe Wechselwirkungen zum Ile155 am 
Rande der S1-Tasche zu generieren, wobei der basische Charakter der 
Guanidinogruppe erhalten bleiben sollte. Es wurde jedoch eine deutlich 
verringerte Wirksamkeit für diese beiden alkylierten Inhibitoren bestimmt 
(Tabelle 3.8). 
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 Inhibitor 77 nimmt eine hufeisenförmige Konformation an, bei der der P4 
Phenylring nah an den P1-Rest kommt. Deshalb wurden erste cyclische Derivate 
synthetisiert, um diese gebundene Konformation bereits in Lösung zu 
stabilisieren und dadurch die Flexibilität der Inhibitoren einzuschränken. In 
einem ersten Ansatz wure eine head to tail Zyklisierung über einen P1'-Linker 
vorgenommen, der an den P4-Rest gekoppelt wurde. Für die beiden zyklischen 
Derivate (Figure 3.5) wurden jedoch nur Hemmkonstanten um 35 µM bestimmt. 
Um eine mögliche Spaltung dieser substratanalogen Strukturen nach dem P1-
Rest zu vermeiden, wurde parallel eine Serie mit unterschiedlichen P'-Resten 
synthetisiert und die Stabilität dieser Inhibitoren nach Inkubation mit der WNV-
Protease mittels HPLC geprüft. Für alle untersuchten Derivate wurde eine relativ 
hohe Stabilität gefunden, die deutlich über der des chromgenen Substrates Phac-
Lys-Lys-Arg-pNA liegt. Für einige lineare Verbindungen wurde eine starke 
inhibitorische Wirksamkeit bestimmt, z.B. hemmt Phac-Lys-Lys-Arg-NH2 (101) 
die WNV-Protease mit einem Ki-Wert von 0,4 µM nach einem reversibel-
kompetitiven Hemmmechanismus. In einem zweiten Ansatz wurde eine 
Zyklisierung durch direkte Kopplung der P1- und P4-Reste vorgenommen. 
Dafür wurde das P4-P2 Segment an die Seitenkette eines Lysin- oder 
Ornithinrestes gekoppelt. Am Ende wurde die α-Aminogruppe der P1-Reste in 
ein Guanidin überführt und deren freie Carboxylfunktion an den P4-Rest 
gekoppelt. Für alle zyklischen Verbindungen wurde jedoch nur eine schwache 
Hemmwirkung bestimmt. 
Im Rahmen dieser Arbeit ist es durch Einbau besonders geeigneter, decarboxylierter 
Argininmimetika gelungen, Hemmstoffe der WNV NS2B-NS3-Protease mit 
Hemmkonstanten um 0,15 µM zu erhalten. Im Vergleich zu den bereits bekannten 
Verbindungen mit Agmatin in P1-Position besitzen die Derivate mit einem trans-4-
Guanidinocyclohexylmethylamid eine erhöhte Selektivität gegenüber einigen 
trypsinartigen Serinproteasen, wie Matriptase. Mit einem der neu entwickelten 
Inhibitoren konnte erstmals eine Kristallstruktur der WNV-Protease mit einem 
nichtkovalent-bindenden niedermolekularen Inhibitor gelöst werden. 
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5 Experimental part 
5.1 Reagents and methods 
5.1.1 Reagents and materials 
Standard chemicals and solvents were obtained from Acros, VWR, Fisher Scientific, 
Fluka, Sigma-Aldrich, Merck, or Roth. The used solvents had p.a or HPLC-grade 
quality. Dry solvents were stored over molecular sieves. The acetonitrile for analytical 
and preparative HPLC was purchased from VWR (HiPerSolv CHROMANORM). Ultra 
pure water was prepared using a NOWA pure select system (KSN Water Technology, 
Nistertal). Aqueous solutions of acids, bases or salts were prepared using demineralized 
water. Trifluoroacetic acid was a gift from Solvay. Amino acids and their derivatives 
were purchased from Bachem, Novabiochem, Orpegen Pharma, PolyPeptide, or IRIS 
Biotech. 
5.1.2 Thin layer chromatography 
Thin layer chromatography (TLC) was performed on precoated "silica gel 60 F254" 
plates from Merck. A mixture of n-butanol/acetic acid/water (4:1:1, v/v/v) was used as a 
mobile phase. The compounds were visualized either by fluorescence detection 
(λex 254 nm), or by spraying with a ninhydrin solution and heating (300 mg ninhydrin 
dissolved in 100 mL n-butanol and 3 mL glacial AcOH) followed by incubation in a 
chlorine gas atmosphere and spraying with an o-toluidine solution (filtered solution of 
150 mg o-toluidine and 2.1 g KI dissolved in 2 mL AcOH and 148 mL water) to reveal 
the spots. 
5.1.3 High performance liquid chromatography (HPLC) 
For all HPLC experiments the following solvents were used: 
 solvent A: 0.1% TFA in ultrapure water 
 solvent B: 0.1% TFA in ACN 
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Analytical HPLC 
Unless otherwise mentioned, all analytical reversed-phase HPLC chromatograms were 
performed using a Shimadzu LC-10A gradient HPLC system consisting of the 
subsystems CTO-10A column oven, LC-10ATvp pumps (2 x), DGU-14A degasser, 
SIL-10Axl autoinjector, SCL-10Avp system controller, SPD-M 10Avp photodiode 
array detector, Shimadzu Class-VP software and a reversed phase column (Nucleodur 
100-5 C18 ec, 250 mm x 4.6 mm, Macherey-Nagel, Düren, Germany). The detection 
was performed at 220 nm. Solvents A and B served as eluents at a flow rate of 
1 mL/min and a linear gradient of 1 % increase in solvent B/min. Different starting 
conditions (1, 10, 20 and 30% B) were used for analytical HPLC depending on the 
properties of the compounds, which are indicated for each derivative. The given purity 
for all intermediates is based on HPLC detection at 220 nm. 
Preparative HPLC 
The final inhibitors were purified using a preparative HPLC system (pumps: Varian 
PrepStar Model 218 gradient system, detector: ProStar Model 320, fraction collector: 
Varian Model 701). The following columns (dimensions 250 mm × 32 mm) were used: 
1. Nucleosil, 300-5 C18, 300 Å, Macherey-Nagel, Düren 
2. Prontosil 120-5-C18-SH, 120 Å, Bischoff Chromatography 
All purifications were performed using a linear gradient of acetonitrile/water containing 
0.1 % TFA at a flow rate of 20 mL/min, using different starting conditions. 
5.1.4 Lyophilization 
All final inhibitors and some intermediates were obtained as TFA salts after preparative 
HPLC followed by lyophilization from water or 80% tert-butanol using a vacuum 
freeze-drying system Alpha 2-4 LD plus (Christ, Osterode am Harz, Germany). 
5.1.5 NMR and mass spectrometry 
1
H and 
13
C spectra were recorded by using ECX-400 (Jeol., USA) at 400 and 100 MHz 
or Jeol Eclipse Plus (Jeol Inc., USA) at 500 and 126 MHz and are referenced to internal 
solvent signals; the chemical shifts are given in ppm. The molecular mass of the 
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synthesized compounds was determined by a QTrap 2000 ESI mass spectrometry 
(Applied Biosystems, USA) or a VG Autospec (Micromass, USA). 
5.2 Enzyme kinetic measurements 
5.2.1 Kinetic measurement with the WNV NS2B-NS3 protease 
All enzyme kinetic measurements with the WNV NS2B-NS3 protease were performed 
using the fluorogenic substrate Phac-Leu-Lys-Lys-Arg-AMC at ex = 380 nm and 
em = 460 nm using a microplate fluorescence plates reader Tecan Safire II (Männedorf, 
Switzerland). The substrate was dissolved and further diluted in ultrapure water, 1 mM 
stock solutions of the inhibitors were prepared and diluted in WNV protease assay 
buffer (100 mM Tris∙HCl pH 8.5 containing 20% glycerol and 0.01% Triton X-100). 
The concentrations of the inhibitors in the assay were at least 200-fold higher than the 
used enzyme concentration. For the calculation of the molecular weight of the 
inhibitors, one TFA molecule was added for each basic group. The measurements were 
performed for 10 min at RT with the following volumina: 
 125 μL buffer pH 8.5 containing the inhibitor  
 50 μL aqueous substrate solution 
 start of reaction with 25 μL enzyme solution  
Ki values < 100 µM were calculated according to the method of Dixon
93
 at three 
different substrate concentrations and six to eight different inhibitor concentrations. The 
inhibition constants for the weaker inhibitors were determined at a substrate 
concentration of 50 µM using equation (1) for competitive reversible inhibition, were 
Vmax is the maximum reaction rate could be achieved by the enzyme, Km is the Michaelis 
Menten constant and S is the substrate concentration 
Equation      
      
  (  
 
  
)  
     (1) 
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5.2.2 Measurements with trypsin-like serine proteases 
Chromogenic p-nitroanilide substrates were used for the determination of the inhibition 
constants (Ki) for the trypsin-like serine proteases matriptase, factor Xa, and thrombin.
94
 
Measurements were performed at 405 nm using a microplate IEMS Reader MF 1401 
(Labsystems, Helsinki, Finland). The substrates were dissolved in ultrapure water, 1 
mM stock solutions of the synthesized inhibitors were prepared in Tris∙HCl buffer pH 
8.0 containing 0.154 M NaCl, and 2 % ethanol. The measurements were performed at 
RT with the following volumina: 
 200 μL buffer pH 8.0 containing the inhibitor 
 25 μL aqueous substrate solution 
 start of reaction with 50 μL enzyme solution  
The measurements were stopped by the addition of 25 µL 50% AcOH after an 
appropriate reaction time, when the absorbance at the highest substrate concentration in 
the absence of an inhibitor had reached a value between 0.15 and 0.18.
94
 The Ki values 
were calculated from Dixon plots
93
 at two substrate concentrations and five inhibitor 
concentrations using an EXCEL template developed by Stürzebecher. The Ki values are 
the mean of at least two independent measurements. 
The used enzyme and substrate concentrations are summarized in Table 5.1. 
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Table 5.1: Used enzymes and substrates. 
Enzyme 
stock and assay concentrations* 
Substrate 
stock  and assay concentrations 
WNV NS2B-NS3 protease
90
 
16 nM (2 nM) 
Phac-Leu-Lys-Lys-Arg-AMC; 
0.8 mM (200 μM in assay) 
0.4 mM (100 μM in assay) 
0.2 mM (50 μM in assay) 
matriptase
a
 (catalytic domain)
95
 
1.44 nM (0.262 nM) 
MeSO2-D-Cha-Gly-Arg-pNA; 
2 mM (182 μM in assay) 
1 mM (91 μM in assay) 
0.5 mM (45.5 μM in assay) 
human factor Xa (fXa)
a
 
200.35 IE/mg, Enzyme Research South Bend 
2.72 nM (0. 494 nM) 
CH3OCO-D-Cha-Gly-Arg-pNA, 
2 mM (182 μM in assay) 
1 mM (91 μM in assay) 
0.5 mM (45.5 μM in assay) 
bovine thrombin
a96
 
1425 IE/mg 
3.725 nM (0.677 nM) 
MeSO2-D-Cha-Gly-Arg-pNA; 
2 mM (182 μM in assay) 
1 mM (91 μM in assay) 
0.5 mM (45.5 μM in assay) 
a
Matriptase, fXa and thrombin stock solutions were prepared in 0.9% NaCl solution containing 0.1% 
HSA or BSA. * The concentrations in the assay are given in brackets. 
5.3 Synthesis 
5.3.1 General synthetic procedures 
The following standard procedures A-Q for the synthesis of precursors, intermediates, 
and inhibitors were performed as described previously in several textbooks.
97, 98
 
Method A 
Loading of Fmoc amino acids on 2-Cl-tritylchlorid (2Cl-Trt-Cl) resin 
The Fmoc amino acid (1 equiv) was suspended in dry DCM and treated with 4 equiv 
DIPEA to reveal a clear solution, which was added to 1 equiv resin in a polypropylene-
syringe for manual SPPS equipped with a PTFE filter (Intavis Bioanalytical 
Instruments, Köln). After 2 h shaking at RT, the reaction solution was removed, and the 
resin was washed 3  1 min with DCM/MeOH/DIPEA (17:2:1, v/v/v), followed by 
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multiple washing with DCM, DMF and again with DCM. The loaded resin was dried in 
vacuum. 
Method B 
Loading of diamines on tritylchlorid resin  
The amino component (4 equiv) was dissolved in dry DCM and loaded to the 
tritylchloride resin as described on method A, followed by an identical washing 
procedure. If the amines were used as salts additional 4 equiv DIEPA was added. 
Method C 
Fmoc solid phase peptide synthesis  
The manual Fmoc SPPS was performed in 2 or 5 mL polypropylene-syringes 
(Multisynthech GmbH, Witten, Germany) equipped with PTFE 
(polytetrafluoroethylene) filters using a standard Fmoc protocol. A solution of 20% 
piperidine in DMF was used for Fmoc cleavage and, after washing with DMF, the 
coupling of the following residue was achieved using 4 equiv of acid, HBTU, and HOBt 
in presence of 8 equiv of DIPEA. The used synthesis cycle is shown in Table 5.2 
Table 5.2: Steps of the used standard SPPS cycle. 
Step Procedure and reagent Time (min) 
1 resin swelling (only for first cycle) 1  10 
2 Fmoc cleavage 1  5 and 1  20 
3 washing with DMF 1 3  1 
4 washing with DMF 2 3  1 
5 washing with DMF 3 2  1 
6 Fmoc amino acid coupling 1  120 
7 washing with DMF 4 3  1 
8 washing with DMF 1 1  1 
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Method D 
Weak acidic cleavage from resin keeping side chain protections 
After completing the SPPS, the peptide was cleaved from the resin using 1% TFA in 
DCM (3  30 min). The solution containing the cleaved peptide was immediately 
neutralized with DIPEA after each cleavage step. Finally, the solvents were removed in 
vacuum. 
Method E  
Strong acidic cleavage from resin 
After completing the SPPS, the peptide was cleaved (approximately 1 h) from resin 
using a mixture of TFA/TIS/H2O (95/2.5/2.5, v/v/v). For intermediates the solvent was 
removed in vacuum and used for the next step.  
If the desired inhibitor/peptide was obtained at this cleavage, the TFA was partially 
removed and the remaining solution was added dropwise to cold diethyl ether. The 
precipitate was obtained by centrifugation, washed with diethyl ether, and dried in 
vacuum. The product was purified by preparative HPLC, and lyophilized from water or 
80% tert-butanol. 
Method F 
PyBOP coupling
99
 
1 equiv of an amino component and 1 equiv of the carboxyl derivative were dissolved in 
DMF (5 mL/mmol) and treated with 1 equiv PyBOP and 2-3 equiv DIPEA to reach a 
pH value between 8.5 and 9.5. The mixture was stirred at 0 °C for 30 minutes and at RT 
for 2 h. The solvent was removed in vacuum. The residue was dissolved in EtOAc and 
washed trice with 5% KHSO4-solution, once with brine, trice with saturated NaHCO3-
solution, and trice with brine. The EtOAc phase was dried over Na2SO4, filtered, and 
the solvent was removed in vacuum. 
Method G 
Cleavage of Cbz-protecting group by HBr/acetic acid
98
 
1 equiv of Cbz-protected compound was dissolved in 32% HBr in glacial AcOH (10 
mL/mmol).The mixture was shaken several times within 1 h at RT. The solvent was 
partially removed in vacuum and the product was precipitated by diethyl ether, filtered, 
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washed with diethyl ether, and dried in vacuum. Alternatively, the product was purified 
by preparative HPLC, and lyophilized from water or 80% tert-butanol. 
Method H 
Introduction of Boc protecting group
98
 
1 equiv of the amino acid was dissolved in a mixture of organic solvent (dioxane or 
acetonitrile) and water (2:1, v/v, 5 mL/mmol) at 0 °C. This mixture was treated with 1.1 
equiv 1 N NaOH and 1.1 equiv di-tert-butyl dicarbonate. The pH was adjusted to 8.5-
9.5 with 1 N NaOH. The mixture was stirred for 3 h at RT, whereby the reaction was 
controlled by HPLC. If necessary, an additional amount of (Boc)2O and 1 N NaOH 
were added and the mixture was further stirred at RT overnight. The solvent was 
removed in vacuum. The residue was dissolved in EtOAc, washed trice with 5% 
KHSO4-solution, and trice with brine. The EtOAc phase was dried over Na2SO4, filtered 
and removed in vacuum. 
Method I 
Cleavage of Boc-protecting group by 90% TFA
100
 
1 equiv of Boc-protected compound was dissolved in 90% TFA (5 mL/mmol) and the 
mixture was stirred for 1 to 2 h at RT. The solvent was removed in vacuum. If the 
desired inhibitor/peptide was obtained at this step, the TFA was partially removed and 
the product was precipitated by diethyl ether, filtered, washed with diethyl ether, and 
dried in vacuum. The product was purified by preparative HPLC, and lyophilized from 
water or 80% tert-butanol. 
Method J 
Hydrogenation
101
 
The compound was dissolved in 90% AcOH and treated with approximately 10 mass 
percent of catalyst (10% Pd/C). The mixture was stirred at least overnight under a 
hydrogen atmosphere. If necessary (HPLC control), the hydrogenation was continued at 
RT for additional 24 h. The catalyst was removed by filtration and the solvent was 
evaporated. Alternatively, the product was purified by preparative HPLC and 
lyophilized from water or 80% tert-butanol. 
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Method K 
Introduction of the Tfa-group 
97
 
1 equiv of the amino component was dissolved in methanol and treated with 1 equiv of 
trifluoroacetic anhydride and 1equiv of DIPEA. The mixture was stirred at 0 °C for 1 h 
and at RT for 2 h. The reaction progress was monitored by HPLC, and if necessary, an 
additional amount of trifluoroacetic anhydride was added and stirring was continued at 
RT overnight. The solvent was removed in vacuum. The remaining residue was 
dissolved in EtOAc and washed trice with 5% KHSO4-solution and trice with brine. The 
EtOAc phase was dried over Na2SO4, filtered and the solvent was removed in vacuum. 
Method L 
Cleavage of the Tfa-protecting group with 1 N NaOH
100
 
The corresponding Tfa-protected amino derivative was dissolved in a mixture of 
dioxane and water (1:1, 10 mL/mmol) and the pH was adjusted to 12 using 1 N NaOH. 
The mixture was stirred for 3 h (HPLC control), and if necessary, stirring was continued 
for some hours until the end of the reaction. The solution was neutralized by the 
addition of 10% TFA and the solvent was removed in vacuum. The product was purified 
by preparative HPLC and lyophilized from 80% tert-butanol. 
Method M 
Conversion of amino into guanidino group
102
 
1 equiv of the free amino intermediate was dissolved in DMF (10 mL/mmol), treated 
with 2 equiv 1H-pyrazole-1-carboxamidine × HCl, and 3 equiv DIPEA. The mixture 
was stirred at RT for 24 h (HPLC control) and if necessary, an additional amount of 1H-
pyrazole-1-carboxamidine × HCl and DIPEA were added, and stirring was continued 
until completion of the reaction. The solvent was removed in vacuum. 
Method N 
Conversion of amino into di-Boc-protected guanidino group
103
 
1 equiv of the free amino intermediate was dissolved in DMF (10 mL/mmol), treated 
with 2 equiv N,N’-di-Boc-1H-pyrazole-1-carboxamidine, and 3 equiv DIPEA. The 
mixture was stirred at RT for 24 h (HPLC control) and if necessary, an additional 
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amount of N,N’-di-Boc-1Hpyrazole-1-carboxamidine and DIPEA were added, and 
stirring was continued until completion of the reaction. The solvent was removed in 
vacuum. 
Method O 
Conversion of amino into methyl/ethyl-guanidine group
88
 
1 equiv of the free amino intermediate was dissolved in DMF (10 mL/mmol), treated 
with 2 equiv 2-Ethyl-1-methyl-isothiourea hydroiodide or 2-Ethyl-1-ethyl-isothiourea 
hydroiodide, and 2 equiv DIPEA. The mixture was stirred at RT for 24 h (HPLC 
control) and if necessary, an additional amount of the guanylation reagent and DIPEA 
were added, and stirring was continued until completion of the reaction. The solvent 
was removed in vacuum. 
Method P 
Introduction of Fmoc protecting group
98
 
1 equiv of the amino derivative was dissolved in ACN (10 mL/mmol) and treated with 
2 equiv NMM or DIPEA. 1 equiv Fmoc-OSu dissolved in ACN
80
 (5 mL/mmol) was 
added in two portions and the mixture was stirred at 0°C for 1h. The pH value was set to 
8.5-9.5 by the addition of NMM or DIPEA. The mixture was stirred at RT for 3 h 
(HPLC control). If necessary, additional amounts of Fmoc-OSu and NMM or DIPEA 
were added and the mixture was further stirred at RT overnight. The solvent was 
removed in vacuum. 
Method Q 
Intramolecular cyclization in solution
89
 
The peptide containing one free amino and one carboxyl group was dissolved in DMF 
(100 mL/0.1mmol). The mixture was treated with 3 equiv BOP and initially with 3 
equiv DIPEA, followed by stirring at 0°C for 1h. During the reaction the pH was 
controlled several times and adjusted to 8.5-9.5 by adding small portions of DIPEA. 
The mixture was stirred at RT for 48-72 h and the reaction progress was controlled by 
HPLC. Finally, the solvent was removed in vacuum, the remaining residue was 
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dissolved in EtOAc and washed with 5% KHSO4-solution and trice with brine. The 
EtOAc phase was dried over Na2SO4, filtered, and the solvent was removed in vacuum. 
5.3.2 Synthesis of the intermediates  
N-(trans-4-carboxycyclohexylmethyl)phtalimide
80
 17a
[2]
 
(1r,4r)-4-((1,3-dioxoisoindolin-2-yl)methyl)cyclohexanecarboxylic acid 
OH
O
N
O
O
 
7.85 g trans-4-(aminomethyl)cyclohexane (50 mmol) suspended in 50 mL THF were 
treated with 10.95 g ethyl 1,3-dioxoisoindoline-2-carboxylate (carboethoxyphtalimide) 
(50 mmol) and 7 mL triethylamine and refluxed for 18 h. The reaction mixture was 
concentrated in vacuum. The remaining oil was treated with 200 mL water containing 5 
mL acetic acid, which resulted in the precipitation of the product. The white solid was 
filtered and dried. 
Yield: 11.7 g (40.7 mmol), white powder. 
HPLC: 46% B (purity: 89.5%).  
N-(trans-4-isocyanato-cyclohexylmethyl)phtalimide
80
 17b 
2-(((1r,4r)-4-isocyanatocyclohexyl)methyl)isoindoline-1,3-dione 
N
N
O
O
C
O
 
11.7 g N-(trans-4-carboxycyclohexylmethyl)phtalimide 17a (40.7 mmol) suspended in 
100 mL carbon tetrachloride was treated with 5 mL thionyl chloride and refluxed for 4 
h. The mixture was cooled and concentrated to approximately 50 % under reduced 
pressure. 7 mL trimethylsilyl azide were added and the mixture was further refluxed for 
                                                 
[2]
 The compound names provided in bold are trivial names and have been used in previous publications, 
in contrast the additional names below were generated according to the IUPAC nomenclature using the 
software ChemOffice Ultra 12.0 (Cambridge Soft). 
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18 h. Finally, the solvent was removed in vacuum providing a brown oil. The crude 
isocyanate was directly used for the next step. 
Boc-N-(trans-cyclohexylmethyl)phtalimide
80
 17c 
tert-butyl (1r,4r)-4-((1,3-dioxoisoindolin-2-yl)methyl)cyclohexylcarbamate 
H
N
N
O
O O
O
 
The crude intermediate 17b was dissolved in 50 mL THF and treated with 3.2 g lithium 
tert.butoxide (40 mmol). The mixture was stirred at RT for 2 h forming a dark solution. 
The mixture was diluted with aqueous acetic acid. The crude product immediately 
precipitated and was recrystallized from 1-chlorobutane. 
Yield: 2.2 g, gray crystals. 
HPLC: 63.8% B (purity: 75%). 
trans-N-(4-tertbutoxycarbonylamino)cyclohexylmethyl amine 
80
 17d 
tert-butyl (1r,4r)-4-(aminomethyl)cyclohexylcarbamate 
H
N
H2N
O
O  
1.5 g Boc-N-(trans-cyclohexylmethyl)phtalimide 17c (6.57 mmol) was treated with 1.6 
mL hydrazine hydrate (50 mmol) in 200 mL isopropanol and stirred for 18 h followed 
by 4 h reflux. The mixture was concentrated, treated with cold aqueous acetic acid and 
filtered to remove the phtalazinedione. The aqueous layer was basified with NaOH, 
followed by extraction with ethyl acetate. The organic layer was dried with MgSO4, 
filtered and evaporated to give the product. 
Yield: 0.9 g, white powder. 
HPLC: 25.7% B (purity: 85.6%). 
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Fmoc-AMCA-Boc 17e 
H
N
H
N
O
O
Fmoc  
0.85 g trans-N-(4-tertbutoxycarbonylamino)cyclohexylmethyl amine 17d (3.7 mmol) 
was treated with 1.25 g Fmoc-OSu (3.7 mmol) according to method P. 
Yield: 1.3 g (2.88 mmol), yellow oil. 
HPLC: 41.2% B (purity: 51.5%). 
trans-(4-Fmoc-aminomethyl)cyclohexylamine  TFA (Fmoc-AMCA  TFA) 17 
(9H-fluoren-9-yl)methyl ((1r,4r)-4-aminocyclohexyl)methylcarbamate 
 
NH2
H
N
Fmoc
x TFA
 
1.3 g of the intermediate 17e (2.88 mmol) was treated with 12 mL TFA according to 
method I. 
Yield: 1.1 g (2.37 mmol), white powder. 
HPLC: 39.9% B (purity: 97.8%); MS calcd: 350.2, found: 351.3 [M+H]
+
; 13C NMR 
([D6]DMSO, 126 MHz): δ = 156.0, 143.8, 140.7, 127.5, 126.9, 125.0, 120.0, 65.0, 49.4, 
46.8, 45.8, 36.5, 29.7, 27.8 ppm). 
Boc-Phe(4-CN)-OH 18a
74
 
(S)-2-(tert-butoxycarbonylamino)-3-(4-cyanophenyl)propanoic acid 
N
H
N
OH
O
Boc
 
1 g H-Phe(4-CN)-OH (5.26 mmol) was treated with 1.262 g di-tert-butyl dicarbonate 
(5.786 mmol) according to method H.  
Yield: 1.566 g (5.4 mmol), white powder. 
HPLC: 45.7% B (purity: 95.6%). 
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Boc-Phe(4-AMe)-OH 18b
74
 
(S)-3-(4-(aminomethyl)phenyl)-2-(tert-butoxycarbonylamino)propanoic acid 
H
N
OH
O
NH
2
Boc
 
1.4 g Boc-Phe(4-CN)-OH 18a (4.85 mmol) was treated with ~ 0.15 g Pd/C according to 
method J. The product was used for the synthesis of intermediate 18c without further 
purification. 
Yield: 1.15 g (3.9 mmol), yellow oil. 
HPLC: 26.9% B (purity: 88.6%). 
Boc-Phe(4-Tfa-AMe)-OH 18c
74
 
(S)-2-(tert-butoxycarbonylamino)-3-(4-((2,2,2-trifluoroacetamido)methyl)phenyl)-
propanoic acid 
H
N
OH
O
H
N
Boc
O
F
F
F
 
1 g Boc-Phe(4-AMe)-OH 18b (3.39 mmol) was treated with 478 µL trifluoroacetic 
anhydrid according to method K. 
Yield: 1.35 g (3.46 mmol), yellow oil. 
HPLC: 48.8% B (purity: 85.3%). 
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Phe(4-AMe-Tfa)-OH  TFA 18d 
(S)-2-amino-3-(4-((2,2,2-trifluoroacetamido)methyl)phenyl)propanoic acid  TFA 
H2N
OH
O
H
N
O
F
F
Fx TFA
 
1 g Boc-Phe(4-AMe-Tfa)-OH 18c ( 2.56 mmol) was treated with ~ 12 mL TFA 
according to method I. The product was dried in vacuum, and used for the synthesis of 
intermediate 18 without further purification. 
Yield: 1.05 g (2.6 mmol as salt), white powder. 
HPLC: 22.6% B (purity: 90.2%). 
Fmoc-Phe(4-AMe-Tfa)-OH 18 
(S)-2-(((9H-fluoren-9-yl)methoxy)carbonylamino)-3-(4-((2,2,2-trifluoroacetamido)-
methyl)phenyl)propanoic acid 
H
N
OH
O
H
N
O
F
F
F
Fmoc
 
1 g Phe(4-AMe-Tfa)-OH  TFA 18d (2.47 mmol) was treated with 0.833 g Fmoc-OSu 
(2.47 mmol, 1 equiv) according to method P. 
Yield: 1.1. g (2.14 mmol), white powder. 
HPLC: 61.7% B (purity: 84.4%). 
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Boc-Phe(3-CN)-OH 19a
74
 
(S)-2-(tert-butoxycarbonylamino)-3-(3-cyanophenyl)propanoic acid 
H
N
OH
O
Boc
N
 
1 g Phe(3-CN)-OH (5.26 mmol) was treated with 1.262 g di-tert-butyl dicarbonate 
(5.786 mmol) according to method H.  
Yield: 1.466 g (5.05 mmol), white powder. 
HPLC: 45.2% B (purity: 90.1%). 
Boc-Phe(3-AMe)-OH 19b
74
 
(S)-3-(3-(aminomethyl)phenyl)-2-(tert-butoxycarbonylamino)propanoic acid 
H
N
OH
O
Boc
NH2
 
1.2 g Boc-Phe(3-CN)-OH 19a (4.14 mmol) was treated with ~ 0.15 g Pd/C according to 
method J. The product was used for the preparation of intermediate 19c without further 
purification.  
Yield: 0.98 g (3.33 mmol), yellow oil. 
HPLC: 26.7% B (purity: 90.4%). 
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Boc-Phe(3-AMe-Tfa)-OH 19c
74
 
(S)-2-(tert-butoxycarbonylamino)-3-(3-((2,2,2-rifluoroacetamido)methyl)phenyl)-
propanoic acid 
H
N
OH
O
Boc
NH
O
F
F
F
 
0.95 g Boc-Phe(3-AMe)-OH 19b (3.23 mmol) was treated with 455µL trifluoroacetic 
anhydrid (3.23 mmol) according to method K. 
Yield: 1.2 g (3.07 mmol), yellow oil. 
HPLC: 46.5% B (purity: 77%). 
H-Phe(3-AMe-Tfa)-OH  TFA 19d 
(S)-2-amino-3-(3-((2,2,2-trifluoroacetamido)methyl)phenyl)propanoic acid  TFA 
H2N
OH
O
NH
O
F
F
F
x TFA
 
1 g Boc-Phe(3-AMe-Tfa)-OH 19c (2.56 mmol) was treated with ~12 mL TFA 
according to method I. The product was precipitated with diethyl ether and separated by 
centrifugation. Finally, the product was dried in vacuum, and used in the synthesis of 
compound 19 without further purification. 
Yield: 0.93g (2.56 mmol as salt), white powder. 
HPLC: 23.3% B (purity: 89.4%). 
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Fmoc-Phe(3-AMe-Tfa)-OH 19 
(S)-2-(((9H-fluoren-9-yl)methoxy)carbonylamino)-3-(3-((2,2,2-trifluoroacetamido)-
methyl)phenyl)propanoic acid 
H
N
OH
O
NH
O
F
F
F
Fmoc
 
1 g Phe(3-AMe-Tfa)-OH  TFA 19d (2.22 mmol) was treated with 0.833 g Fmoc- OSu 
(2.22 mmol)) according to method P. 
Yield: 1.05. g (2.05 mmol), white powder. 
HPLC: 60.2% B (purity: 88.4%). 
Fmoc-Phe(4-NO2)-OH 20 
(S)-2-(((9H-fluoren-9-yl)methoxy)carbonylamino)-3-(4-nitrophenyl)propanoic acid 
H
N
NO2
O
OHFmoc
 
1 g Phe(4-NO2)-OH (4.75 mmol) was treated with 1.60 g Fmoc-OSu (4.75 mmol) 
according to method P. 
Yield: 1.3 g, (3.01 mmol), white powder. 
HPLC: 63.3% B (purity: 91.9%). 
2-Ethyl-1-methyl-isothiourea hydroiodide
88
 21 
N NH2
S
I-
 
2.166 g 1-methylthiourea (24 mmol) was dissolved in 5 mL absolute ethanol, treated 
with 1.93 mL iodoethan (24 mmol) and stirred at 60°C for 4 h. The reaction mixture 
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was concentrated in vacuum. The product was obtained as mobile yellowish oil and was 
used later without further purification. 
Yield: 5.6 g (22.9mmol), yellowish oil, MS calcd: 118.06, found: 119.06 (M+H)
+
. 
TLC: Rf = 0.46  
2-Ethyl-1-ethyl-isothiourea hydroiodide
88
 22 
N NH2
S
I-
 
2.5 g 1-ethylthiourea (24 mmol) were converted into 2-ethyl-1-ethyl-isothiourea 
hydroiodide in analogy to the synthesis of derivative 21. The intermediate 22 was 
obtained as mobile yellowish oil and was further used without purification. 
Yield: 6.1 g (23.5mmol), yellowish oil, MS calcd: 132.07, found: 133.05 (M+H)
+
.  
TLC: Rf = 0.47  
5.3.3 Synthesis of inhibitors 23-39 containing different P1 residues  
Inhibitors 23-32, 38 and 39 
0.1 g trityl chloride resin (loading 1.5 mmol/g) was treated with the unprotected 
diamines or with Fmoc-(aminomethyl)cyclohexanamine 17 according to method B. 
After resin loading (method A), standard Fmoc-protocol as described in method C was 
used for the subsequent solid phase peptide synthesis to assemble the amino acids and 
the terminal phenylacetyl-residue. After the final coupling step, the peptides with the 
general formula Phac-Lys(Cbz)-Lys(Cbz)-X (X: different P1 diamines) were cleaved 
from the resin using a mixture of 95 % TFA, 2.5 % H2O and 2.5 % TIS (method E) to 
obtain the intermediates 23a, 25a, 27a 29a, 31a and 38a.  
The half amount of these amine intermediates were converted into their corresponding 
guanidine analogues according to method M, which provided the intermediates 24a, 
26a, 28a, 30a and 39a.  
The Cbz protecting group of these intermediates were cleaved using HBr/acetic acid as 
described in method G to provide the corresponding inhibitors. All inhibitors were 
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precipitated by diethyl ether, filtered, washed with diethyl ether, and finally purified by 
preparative HPLC, and lyophilized from water or 80% tert-butanol (Scheme3.1). The 
analytical data of the inhibitors 23-32, 38 and 39 and their related intermediates 23a-
32a, 38a and 39a are summarized in Table 5.3.  
Table 5.3: Analytical characterization of the WNV protease inhibitors with the general formula Phac-
Lys-Lys-P1. The numbers of their corresponding side-chain protected intermediates Phac-Lys(Cbz)-
Lys(Cbz)-P1 are labeled with index a. 
No. P1 
HPLC 
 (% B) 
Purity 
(%) 
MS (calcd/found) 
(M+H)
+
 
23 (MI-0631) H
N NH2  
16.8 99.0 448.3/449.4 
23a 47.5 59.2 n.b. 
24 (MI-0638) H
N
H
N NH2
NH

 
18.5 91.5 490.3/491.0 
24a 48.8 - n.b. 
25 (MI-0629) 
H
N
NH2  
17.3 99.0 462.3/463.5 
25a 49.8 96.8 n.b. 
26 (MI-0637) 
H
N
N
H
NH2
NH

 
19.4 97.0 504.4/505.2 
26a 51.1 - n.b. 
27 (MI-0632) 
H
N NH2  
18.4 99.0 476.3/477.4 
27a 50.1 45.3 n.b. 
28 (MI-0635) H
N
H
N NH2
NH

 
20.7 99.0 518.4/519.3 
28a 51.3 - n.b. 
29 (MI-0639) 
H
N
NH2
  
20.0 99.0 510.3/511.4 
29a 49.0 56.2 n.b. 
30 (MI-0642) 
H
N
N
H
NH2
NH

 
21.4 96.5 552.4/553.6 
30a 50.4 - n.b. 
31 (MI-0633) 
H
N NH2  
20.8 99.0 510.3/511.4 
31a 49.8 52.2 n.b. 
32 (MI-0636) 
H
N
H
N NH
NH2

22.8 92.5 552.4/553.4 
32a 50.9 - n.b. 
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38 (MI-0645) 
H
N
NH2
  
18.5 99.0 502.4/503.2 
38a 51.5 39.0 n.b. 
39 (MI-0646) 
H
N
H
N NH2
NH
  
21.5 99.0 544.3/545.3 
39a 52.9 - n.b. 
The crude guanylated intermediates labeled with index a were directly used for final deprotection, 
therefore, no purity is given for these analogues. 
Inhibitors 33-37 
The intermediate Phac-Lys(Cbz)-Lys(Cbz)-OH was obtained using 0.1 g 2-chlorotrityl 
chloride resin (1.57 mmol/g) for each inhibitor, which was loaded with Fmoc-Lys(Cbz)-
OH according to method a. After washing, Fmoc-Lys(Cbz)-OH and the phenylacetyl-
residue were coupled as described in method c. The peptide was cleaved from resin as 
mentioned in method E. The solvent was removed in vacuum providing the oily Phac-
Lys(Cbz)-Lys(Cbz)-OH (HPLC: 56.5% B, purity: 86.6%). 
This intermediate was further coupled with 4-(aminomethyl)aniline, 3-
(aminomethyl)aniline or 4-aminobenzimidamide according to method F to provide the 
Cbz protected intermediates 33a, 35a and 37a.  The half amount of analogues 33a and 
35a and the complete intermediate 37a were deprotected as described in method G to 
obtain the corresponding inhibitors 33, 35, and 37. The half amount of the Cbz-
protected intermediates 33a and 35a were treated with N,N’-di-Boc-1H-pyrazole-1-
carboxamidine according to method N to obtain the derivatives 34a and 36a, followed 
by deprotection using HBr/acetic acid (method G) to reveal the inhibitors 34 and 36. 
The inhibitors were precipitated by diethyl ether, filtered, washed with diethyl ether, 
and finally purified by preparative HPLC, and lyophilized from water (Scheme3.2). The 
analytical data of the inhibitors 33-37 and their related intermediates 33a-37a are given 
in the Table 5.4.  
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Table 5.4: Analytical characterization of WNV protease inhibitors and their corresponding intermediates 
with the general formula Phac-Lys-Lys-P1 and Phac-Lys(Cbz)-Lys(Cbz)-P1, which are labeled with the 
index a.  
No. P1 HPLC (% B) Purity (%) 
MS (calcd/found) 
(M+H)
+
 
33 (MI-0640) 
H
N
NH2
  
17.4 99.0 496.3/497.3 
33a 48.2 - n.d. 
34 (MI-0643) 
34, R = H
34a, R = Boc
H
N
H
N
H
N
N

R
R
 
20.6 94.6 538.3/539.6 
34a 70.4 - n.d. 
35 (MI-0641) 
H
N
NH2  
18.9 98.2 496.3/497.3 
35a 49.1 - n.d. 
36 (MI-0644) 
H
N
N
H
N
H
N

R
R
36, R = H
36a , R = Boc
 
20.4 99.0 538.3/539.6 
36a 71.3 - n.d. 
37 (MI-0324) 
H
N
NH
NH2
  
20.7 99.0 523.3/262.7
[a]
 
37a 49.9 - n.d. 
[a]
(M+2H)
2+
/2 
5.3.4 Synthesis of inhibitors 40-45 containing Phe(3/4-AMe) 
0.1 g 2-chlorotrityl chloride resin (1.57 mmol/g) was loaded with the corresponding 
protected amino acids Fmoc-Lys(Boc)-OH, Fmoc-Phe(4-AMe-Tfa)-OH or Fmoc-
Phe(3-AMe-Tfa)-OH according to method A. After washing and Fmoc removal the 
following residues were coupled by standard SPPS as described in method C. The 
peptides were cleaved from resin using mild acidic conditions according to method D to 
obtain the side chain protected Phac-P3-P2-OH intermediates labeled with index a. 
These derivatives were coupled with (1r,4r)-benzyl 4-(aminomethyl)cyclohexane-
carboxylate in solution according to method F to provide intermediates with the general 
formula Phac-P3-P2-AMCA-Cbz labeled with index b. The Cbz protecting group was 
cleaved as described in method J to give the intermediates of the general formula Phac-
P3-P2-AMCA labeled with index c. Afterwards, the amino group at P1 residue was 
converted into a free guanidine or Boc-protected guanidine according to the methods N 
or O, respectively, providing the intermediates labeled with index d. The side chain Tfa 
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protecting group was cleaved under basic conditions as described in method L. If 
necessary, this was followed by an acidic cleavage of the Boc protection using method I 
(see Scheme 3.3). The analytical data of the final inhibitors 40-45 and their related 
intermediates are shown in the Table 5.5. 
Table 5.5: Analytical characterization of WNV protease inhibitors 40-45 and their intermediates with the 
general formula 
 
P3
P2
R
O
 
a: R = OH
b: R =
H
N
H
N
Cbz
NH2
H
Nc: R =
H
N
H
N
HN
N
* *
*
d: R = Boc
Boc
H
N
H
N
NH2
NH
*
Inhibitors: R =
 
No. P3 P2 
HPLC 
(% B) 
Purity 
(%) 
MS 
(calcd/found) 
(M+H)
+
 
40 (MI-0648) Phe(4-AMe) Lys 22.14 99.0 592.4/593.2 
40a Phe(4-AMe-Tfa) Lys(Boc) 56.1 47.1 n.d. 
40b Phe(4-AMe-Tfa) Lys(Boc) 67.1 - n.d 
40c Phe(4-AMe-Tfa) Lys(Boc) 47.1 - n.d 
40d Phe(4-AMe-Tfa) Lys(Boc) 49.6 - n.d 
41 (MI-0649) Lys Phe(4-AMe) 21.5 99.0 592.4/593.1 
41a Lys(Boc) Phe(4-AMe-Tfa) 56.0 79.8 n.d 
41b Lys(Boc) Phe(4-AMe-Tfa) 67.5 - n.d 
41c Lys(Boc) Phe(4-AMe-Tfa) 47.6 - n.d 
41d Lys(Boc) Phe(4-AMe-Tfa) 49.8 - n.d 
42 (MI-0647) Phe(4-AMe) Phe(4-AMe) 25.11 97.2 640.4/641.2 
42a Phe(4-AMe-Tfa) Phe(4-AMe-Tfa) 55.7 24.4 n.d 
42b Phe(4-AMe-Tfa) Phe(4-AMe-Tfa) 66.2 - n.d 
42c Phe(4-AMe-Tfa) Phe(4-AMe-Tfa) 47.1 - n.d 
42d Phe(4-AMe-Tfa) Phe(4-AMe-Tfa) 49.1 - n.d 
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43 (MI-0656) Phe(3-AMe) Lys 24.3 99.0 592.4/297.4
[a]
 
43a Phe(3-AMe-Tfa) Lys(Boc) 56.3 54.2 n.d 
43b Phe(3-AMe-Tfa) Lys(Boc) 67.4 - n.d 
43c Phe(3-AMe-Tfa) Lys(Boc) 47.9 - n.d 
43d Phe(3-AMe-Tfa) Lys(Boc) 48.5 - n.d 
44 (MI-0653) Lys Phe(3-AMe) 24.9 99.0 592.4/593.3 
44a Lys(Boc) Phe(3-AMe-Tfa) 57.1 88.2 n.d 
44b Lys(Boc) Phe(3-AMe-Tfa) 67.4 - n.d 
44c Lys(Boc) Phe(3-AMe-Tfa) 48.1 - n.d 
44d Lys(Boc) Phe(3-AMe-Tfa) 50.2 - n.d 
45 (MI-0655) Phe(3-AMe) Phe(3-AMe) 26.7 99.0 640.4/641.4 
45a Phe(3-AMe-Tfa) Phe(3-AMe-Tfa) 57.1 49.2 n.d 
45b Phe(3-AMe-Tfa) Phe(3-AMe-Tfa) 67.2 - n.d 
45c Phe(3-AMe-Tfa) Phe(3-AMe-Tfa) 47.8 - n.d 
45d
[b]
 Phe(3-AMe-Tfa) Phe(3-AMe-Tfa) 65.8 - n.d 
[a]
(M+2H)
2+
/2, [b]only in case of intermediate 45d the P1 guanidine is di-Boc protected. 
5.3.5 Synthesis of inhibitors 46-51 containing Phe(3/4-GMe) 
To obtain inhibitors containing an additional guanidine group in the side chain at their 
Phe residues, the Tfa protection from intermediates 40c-45c was removed under basic 
conditions using 1 N NaOH according to method L. This provided intermediates 46a-
51a, which were treated with a guanylation reagent according to methods N or O to give 
inhibitors 48 and 51 and the intermediates 46b, 47b, 49b and 50b. These intermediates 
labeled with index b were further treated with 90% TFA according to method I to obtain 
the inhibitors 46, 47, 49 and 50 (see Scheme 3.3). The analytical data of these 
compounds and their related intermediates are shown in Table 5.6.  
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Table 5.6: Analytical characterization of WNV protease inhibitors 46-51 and their intermediates with the 
general formula 
P3
P2
R
O
 
NH2
H
N
a: R =
H
N
H
N
NH
2
NH
* *b and all inhibitors: R =  
No. P3 P2 
HPLC 
(% B) 
Purity 
(%) 
MS 
(calcd/found) 
(M+H)
+
 
46 (MI-0651) Phe(4-GMe) Lys 22.9 94.5 634.4/635.2 
46a Phe(4-AMe) Lys(Boc) 29.4 - n.d 
46b Phe(4-GMe) Lys(Boc) 36.3 - n.d 
47 (MI-0650) Lys Phe(4-GMe) 23.4 99 634.4/635.1 
47a Lys(Boc) Phe(4-AMe) 38.1 - n.d 
47b Lys(Boc) Phe(4-GMe) 39.8 - n.d 
48 (MI-0652) Phe(4-GMe) Phe(4-GMe) 27.9 99 724.4/725.3 
48a Phe(4-AMe) Phe(4-AMe) 23.1 - n.d 
49 (MI-0657) Phe(3-GMe) Lys 20.7 99 634.4/635.2 
49a Phe(3-AMe) Lys(Boc) 54.7 - n.d 
49b
[b]
 Phe(3-GMe(Boc)2) Lys(Boc) 39.4 - n.d 
50 (MI-0654) Lys Phe(3-GMe) 25.4 99 634.4/635.3 
50a Lys(Boc) Phe(3-AMe) 34.4 - n.d 
50b
[a]
 Lys(Boc) Phe(3-GMe(Boc)2) 65.6 - n.d 
51 (MI-0658) Phe(3-GMe) Phe(3-GMe) 29.5 99 724.4/725.3 
51a Phe(3-AMe) Phe(3-AMe) 24.1 - n.d 
[a]
This intermediates have the general formula Phac-P3-P1-GCMA(Boc)2, 
[b]
only in case of intermediate 
49d the P1 guanidine is di-Boc protected. 
5.3.6 Synthesis of the inhibitors 52-53 containing Phe(4-Gua) 
0.1 g 2-chlorotrityl chloride resin (1.57 mmol/g) was loaded with Fmoc-Phe(4-NO2)-
OH or Fmoc-Lys(Boc)-OH according to method A. The additional residues were 
coupled by standard Fmoc-SPPS as described in method C. The side chain protected 
intermediates Phac-Lys(Boc)-Phe(4-NO2)-OH  (52a) and Phac-Phe(4-NO2)-Lys(Boc)-
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OH (53a) were obtained after mild acidic cleavage from the resin according to 
method D. The intermediates were coupled to (1r,4r)-benzyl 4-
(aminomethyl)cyclohexane-carboxylate in solution as described in method F to provide 
compounds 52b and 53b. The concomitant reduction of the nitro group and Cbz-
deprotection by hydrogenation (method J) provided the Phe(4-NH2)-containing 
intermediates 52c and 53c. Both amino groups of these intermediates were converted 
into the di-Boc-protected guanidines 52d and 53d using method N, followed by final 
removal of the Boc-protection by method I (see Scheme 3.4). The analytical data of 
inhibitors 52-53 and their related intermediates are shown in Table 5.7.  
Table 5.7: Analytical characterization of WNV protease inhibitors 52-53 and their corresponding 
precursors with index a, b, c and d possessing the general formula. 
O
P3
P2
R
 
a: R = OH
b: R =
H
N
H
N
Cbz
NH2
H
Nc: R =
H
N
H
N
HN
N
*
*
*
d : R = Boc
Boc
H
N
H
N
NH2
NH
*
Inhibitors : R =
 
No. P3 P2 
HPLC 
(% B) 
Purity 
(%) 
MS 
(calcd/found) 
(M+2H)
2+
/2 
52 (MI-0659) Lys Phe(4-Gua) 26.2 98.0 620.4/311.3 
52a Lys(Boc) Phe(4-NO2) 56.1 96.8 n.d 
52b Lys(Boc) Phe(4-NO2) 67.4 - n.d 
52c Lys(Boc) Phe(4-NH2) 35.6 - n.d 
52d Lys(Boc) Phe(4-Gua(Boc)2) 72.7 - n.d 
53 (MI-0660) Phe(4-Gua) Lys 25.8 99.0 620.4/311.5 
53a Phe(4-NO2) Lys(Boc) 55.8 93.9 n.d 
53b Phe(4-NO2) Lys(Boc) 67.3 - n.d 
53c Phe(4-NH2) Lys(Boc) 34.4 - n.d 
53d Phe(4-Gua(Boc)2) Lys(Boc) 72.2 - n.d 
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5.3.7 Synthesis of inhibitors 54-75 modified in P4 position 
0.1 g trityl chloride resin (1.5 mmol/g) was loaded with butan-1,4-diamin according to 
method B. The P2-P4 segment was coupled by standard Fmoc-SPPS using  Fmoc-
Lys(Cbz)-OH and different P4 residues (see Table 5.8) according to the method C. The 
derivatives 54a-75a with the general formula P4-Lys(Cbz)-Lys(Cbz)-4-
aminobutylamide were cleaved from resin as described in method E. The free amino 
group at their C-terminus was converted into a guanidine as described in method M, 
which provided the agmatine intermediates 54b-75b. Finally, the Cbz protecting groups 
of both lysine side chains were cleaved using 2 mL HBr/acetic acid (method G). The 
inhibitors 54-75 were purified by preparative HPLC, and lyophilized from water or 80% 
tert-butanol. The analytical data of the inhibitors and their related intermediates are 
shown in the Table 5.8.  
 
Table 5.8: Analytical characterization of inhibitors 54-75 with the general formula P4-Lys-Lys-agmatine 
and their corresponding Cbz-protected intermediates labeled with index a or b with the general formulas 
P4-Lys(Cbz)-Lys(Cbz)- 4-aminobutylamide and P4-Lys(Cbz)-Lys(Cbz)-agmatine, respectively. 
No. P4 HPLC (% B) Purity (%) 
MS (calcd/found) 
(M+H)
+
 
54 (MI-0662) 
O
O
*
 
32.2 99.0 608.4/609.3 
54a 58.5 98.3 n.d. 
54b 60.1 - n.d. 
55 (MI-0666) 
HO
*
O
 
17.7 97.7 534.4/535.5 
55a 47.1 70.0 n.d. 
55b 47.8 - n.d. 
56 (MI-0661) 
*
O
 
30.2 97.0 480.4/481.2 
56a 55.9 94.8 n.d. 
56b 57.2 - n.d. 
57 (MI-0668) 
*
O
 
25.5 99.0 554.4/555.4 
57a 53.0 95.6 n.d. 
57b 54.3 - n.d. 
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58 (MI-0665) 
H3C
*
O
 
21.4 99.0 518.4/519.4 
58a 51.6 97.0 n.d. 
58b 52.8 - n.d. 
59 (MI0664) 
CH3
*
O
 
21.5 99.0 518.4/519.4 
59a 51.4 94.8 n.d. 
59b 52.5 - n.d. 
60 (MI-0676) O
O
*  
20.3 97.7 548.3/549.4 
60a 48.5 96.3 n.d. 
60b 50.0 - n.d. 
61 (MI-0674) 
H3CO
O
*  
20.6 96.0 534.4/535.4 
61a 48.9 93.6 n.d. 
61b 50.2 - n.d. 
62 (MI-0667) 
HO
O
*  
15.9 95.4 520.3/521.1 
62a 46.3 74.8 n.d. 
62b 47 - n.d. 
63 (MI-0669) 
O2N
O
*  
21.5 99.0 549.3/550.4 
63a 50.3 83.6 n.d. 
63b 51.5 - n.d. 
64 (MI-0673) 
F
O
*  
20.8 99.0 522.3/523.4 
64a 50.5 79.2 n.d. 
64b 51.4 - n.d. 
65 (MI-0677) 
F
O
*  
20.8 99.0 522.3/262.24
[a]
 
65a 49.6 92.6 n.d. 
65b 51.5 - n.d. 
66 (MI-0681) 
O
*
F  
19.8 97.0 522.3/262.25
[a]
 
66a 49.5 57.5 n.d. 
66b 50.9 - n.d. 
67 (MI-0675) 
F3C
O
*  
26.6 98.0 572.3/287.27
[a]
 
67a 53.2 89.2 n.d. 
67b 54.7 - n.d. 
68 (MI-0670) 
Br
O
*  
24.5 99.0 582.3/583.3 
68a 52.8 89.8 n.d. 
68b 53.8 - n.d. 
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69 (MI-0671) 
Br
O
*  
22.5 99.0 582.3/583.4 
69a 51.7 80.5 n.d. 
69b 53.6 - n.d. 
70 (MI-0672) 
Cl
O
* 
23.9 99.0 538.3/539.3 
70a 52.6 79.3 n.d. 
70b 53.3 - n.d. 
71 (MI-0682) 
Cl
O
* 
23.3 98.2 538.3/270.3
[a]
 
71a 51.7 64.4 n.d. 
71b 52.9 - n.d. 
72 (MI-0678) 
Cl
O
*  
21.7 99.0 538.3/270.23
[a]
 
72a 50.3 88.5 n.d. 
72b 51.9 - n.d. 
73 (MI-0680) 
ClCl
O
* 
25.8 99.0 572.3/287.3
[a]
 
73a 53.7 92.2 n.d. 
73b 54.8 - n.d. 
74 (MI-0663) 
Cl
Cl
O
* 
27.0 99.0 572.3/573.3 
74a 53.9 92.0 n.d. 
74b 56.0 - n.d. 
75 (MI-0679) Cl
Cl
O
*  
25.1 99.0 572.3/287.3
[a]
 
75a 52.6 90.7 n.d. 
75b 54.0 - n.d. 
[a]
(M+2H)
2+
/2 
5.3.8 Synthesis of inhibitors 76-78 containing best P1 and P4 residues 
The inhibitors 76-78 were synthesized in analogy to inhibitors 54-75, whereby the resin 
was initially loaded with Fmoc-AMCA  TFA (17). The intermediates a with the 
formula P4-Lys(Cbz)-Lys(Cbz)-AMCA were treated with the guanylation reagent N,N’-
di-Boc-1H-pyrazole-1-carboxamidine according to method N to give the derivatives 
marked with index b with the formula P4-Lys(Cbz)-Lys(Cbz)-GCMA(Boc)2, which 
were finally deprotected using HBr/acetic acid (method G). The inhibitors were purified 
by preparative HPLC, and lyophilized from water or 80% tert-butanol. The analytical 
data of the inhibitors and their related intermediates are shown in Table 5.9.  
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Table 5.9: Analytical characterization of WNV protease inhibitors 76-78 with the general formula P4-
Lys-Lys-GCMA and the corresponding intermediates a and b. with the general formulas P4-Lys(Cbz)-
Lys(Cbz)- AMCA and P4-Lys(Cbz)-Lys(Cbz)-GCMA, respectively. 
No. P4 HPLC (% B) Purity (%) 
MS (calcd/found) 
(M+H)
+
 
76 (MI-0680) 
ClCl
O
* 
27.1 99 612.3/613.4 
76a 53.5 78.9 n.d. 
76b 71.2 - n.d. 
77 (MI-0663) 
Cl
Cl
O
*  
28.3 99 612.3/613.4 
77a 54.1 70 n.d. 
77b 71.1 - n.d. 
78 (MI-0679) Cl
Cl
O
*  
26.4 99 612.3/613.4 
78a 53 78.7 n.d. 
78b 70.5 - n.d. 
Additional analytical data were obtained for compound 78: 1H NMR ([D6]DMSO, 500 
MHz): δ =8.33 (d, J=7.7 Hz, 1H), 7.90 (d,J=8.0 Hz, 1H), 7.86 (t, J=5.9 Hz, 1H), 7.78 
(br s, 5 H), 7.61-7.66 (m,1 H), 7.51–7.55 (m, 1 H), 7.28–7.36 (m, 2 H), 4.22–4.28 (m, 1 
H), 4.16–4.22 (m, 1 H), 3.68–3.78 (m, 2H), 2.89–2.97 (m, 1H), 2.82–2.89 (m,1 H), 
2.70–2.79 (m, 4 H), 1.82–1.90 (m, 2 H), 1.59–1.73 (m, 4 H), 1.46–1.59 (m, 6 H), 1.21–
1.41 (m, 6H), 1.08–1.18 (m, 2H), 0.87–0.98 ppm(m, 2H); 13C NMR ([D6]DMSO,126 
MHz): δ =171.3, 171.2, 168.8,155.8, 137.0, 131.7, 131.5, 130.5, 128.8, 127.8, 52.6, 
52.3, 49.8, 44.3,40.5, 38.7, 38.7, 36.2, 31.7, 31.5, 31.2, 28.6, 26.6, 26.5, 22.3,22.2 ppm; 
HRMS (ESI+): m/z (%): 613.3143 [M+H]
+
). 
Synthesis of P2 and P3 modified agmatine derivatives 79-88 
The inhibitors 81-88 were synthesized in analogy to the agmatine derivative 26 using 
various P2 and P3 amino acids (Fmoc-Lys(Boc), Fmoc-Arg(Pbf)-OH, Fmoc-hPhe-OH, 
Fmoc-Ser(Bzl)-OH or Fmoc-D/L-hAla(2-Pyr)-OH) and 3,4-dichloro-phenylacetic acid 
as  P4 group. The intermediates 81a-88a were obtained after mild acidic cleavage from 
resin according to method D, followed by conversion of their C-terminal amine into 
guanidine to give derivatives 81b-88b (method M). Final side chain deprotection using 
method I provided inhibitor 81-88. 
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The inhibitor 79 was prepared from the loaded trityl chloride resin with butan-1,4-
diamin, which was coupled with Fmoc-Dab(Boc)-OH, Fmoc-Lys(Cbz)-OH and 3,4-
dichloro-phenylacetyl residue as described previously for the analogue 81. The cleavage 
of the peptide from resin was performed using method E to give intermediate 79a with 
the formula 3,4-dichloro-phenylacetyl-Lys(Cbz)-Dab-4-aminobutylamide. The P1 
4-aminobutylamide and the Dab side chain were concomitant converted into agmatine 
and norArg residues, respectively (method M). The Cbz side chain protection of 
intermediate 3,4-dichloro-phenylacetyl-Lys(Cbz)-norArg-agmatine (79b) was removed 
using method G to provide inhibitor 79 (see Scheme 3.5).  
Inhibitor 80 was synthesized in analogy to 79, whereby P2 and P3 were reversed to give 
3,4-dichloro-phenylacetyl-norArg-Lys-agmatine. The final products were purified by 
preparative RP-HPLC, and lyophilized from water or 80% tert-butanol. The analytical 
data of the inhibitors 79-88 and their related intermediates are shown in the Table 5.10.  
 
Table 5.10: Analytical characterization of WNV protease inhibitors 79-88 with the general formula 3,4-
dichloro-phenylacetyl-P3-P2-agmatine and the corresponding intermediates a and b.  
No. P3 P2 P1 
HPLC  
(% B) 
Purity  
(%) 
MS 
(calcd/found) 
(M+H)
+
 
79 (MI-0686) Lys norArg Agm 28.3 99 586.3/294.2
[a]
 
79a Lys(Cbz) Dab Dib 41.2 68.2 n.d. 
79b Lys(Cbz) norArg Agm 43 - n.d. 
80 (MI-0687) norArg Lys Agm 28.2 99 586.3/587.2 
80a Dab Lys(Cbz) Dib 40.3 68 n.d. 
80b norArg Lys(Cbz) Agm 42.5 - n.d. 
81 (MI-0693) Lys Arg Agm 28.2 99 600.3/601.3 
81a Lys(Cbz) Arg Dib 42.1 - n.d. 
81b Lys(Cbz) Arg Agm 43.3 - n.d. 
82 (MI-0694) Arg Arg Agm 29.3 98 628.3/629.3 
82a Arg Arg Dib 28.5 69.7 n.d. 
83 (MI-0691) Lys hPhe Agm 40.3 97.5 605.3/606.3 
83a Lys(Boc) hPhe Dib 52.1 91.9 n.d. 
83b Lys(Boc) hPhe Agm 53.7 - n.d. 
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84 (MI-0692) hPhe Lys Agm 40.8 97.2 605.3/606.3 
84a hPhe Lys(Boc) Dib 52.6 91.9 n.d. 
84b hPhe Lys(Boc) Agm 54.2 - n.d. 
85 (MI-0697) Lys Ser(Bzl) Agm 39.4 99 621.3/622.3 
85a Lys(Boc) Ser(Bzl) Dib 51.7 83.7 n.d. 
85b Lys(Boc) Ser(Bzl) Agm 53.1 - n.d. 
86 (MI-0698) Ser(Bzl) Lys Agm 40.1 99 621.3/622.2 
86a Ser(Bzl) Lys(Boc) Dib 52.5 92.3 n.d. 
86b Ser(Bzl) Lys(Boc) Agm 53.9 - n.d. 
87 (MI-0699) Lys D/L-hAla(2-Pyr) Agm 28.5- 29.1 49.7-48.1 606.3/607.3 
87a Lys(Boc) D/L-hAla(2-Pyr) Dib 40.3 92.8 n.d. 
87b Lys(Boc) D/L-hAla(2-Pyr) Agm 41.4-41.8 - n.d. 
88 (MI-0731) D/L-hAla(2-Pyr) Lys Agm 29.5 99 606.3/607.3 
88a D/L-hAla(2-Pyr) Lys(Boc) Dib 40.1 94.2 n.d. 
88b D/L-hAla(2-Pyr) Lys(Boc) Agm 41.7 - n.d. 
[a]
(M+2H)
2+
/2 , only in this Table the abreviations Agm and Dib stand for agmatine and butane-1,4-
diamine, respectively. Fmoc-D/L-hAla(2-Pyr)-OH was prepared from racemic H-D/L-hAla(2-Pyr)-OH 
available from previous studies
104
 
5.3.9 Synthesis of inhibitors 89 and 90 with alkylated P1 guanidines 
0.1 g of trityl chloride resin (1.55 mmol/g) was loaded with 1 equiv 
Fmoc-AMCA  TFA (17) as described in method B, followed by twice coupling of 
Fmoc-Lys(Boc)-OH and of 3,4-dichlorophenyl acetic acid using a standard Fmoc-SPPS 
protocol according to method C. The intermediate 89a (3,4-dichlorophenylacetyl-
Lys(Boc)-Lys(Boc)-AMCA) was obtained as a yellowish oil after mild cleavage from 
the resin according to method D. (HPLC:53.2% B (purity: 90.1%)). Its C-terminal 
amino group was guanylated using 2-ethyl-1-methylisothiouronium iodide (21) as 
described in method O to give the methylguanidine derivative 89b as yellowish oil. The 
intermediate 90b was synthesized in analogy to derivative 89b, whereby the amino 
group at the C-terminus was converted into an ethylguanidine by treatment with 2-
ethyl-1-ethylisothiouronium iodide (22) according to method O. 
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Finally, the Boc protecting groups of compounds 89b and 90b were removed using 
TFA (method I) (see Scheme 3.6). The analytical data of the inhibitors 89 and 90 and 
their related intermediates 89b and 90b are shown in Table 5.11.  
Table 5.11: Analytical characterization of inhibitors 89 and 90 with the general formula 3,4-dichloro-
phenylacetyl-Lys-Lys-P1 and the corresponding intermediates 89b and 90b.  
H
N
N
H
H
N
H
N
O
O
O
HN
NH
Cl
Cl
HN
NH
R
R`
R`  
No. R R` HPLC (% B) Purity (%) 
MS (calcd/found) 
(M+2H)
2+
/2 
89 (MI-0734) 
Methyl 
H 30.8 99 626.32/314.3 
89b Boc 55.9 - n.d. 
90 (MI-0733) 
Ethyl 
H 31.9 99 640.34/321.01 
90b Boc 57.3 - n.d. 
5.3.10 Synthesis of linearpeptides 91-105 
All peptides were synthesized by SPPS on Fmoc-Rink-Amide resin (0.45 mmol/g) 
using a standard Fmoc protocol according to method C. The peptides were cleaved from 
the resin as described in method E and were finally precipitated in diethyl ether. After 
centrifugation, the precipitate was washed twice with diethyl ether, and after repeated 
centrifugation finally dried in vacuum. The peptides were purified by preparative 
HPLC, and lyophilized from water or 80% tert-butanol. The analytical data of inhibitors 
91-105 are summarized in Table 5.12. The purity of all peptides was ≥ 95%. 
  
Experimental part 
110 
 
Table 5.12: Analytical characterization of peptide amides 90 - 105 with the general formulas P4-Lys-
Lys-P1-R 
No. P4 P1 R 
HPLC 
(% B) 
MS (calcd/found) 
(M+H)
+
 
91 (MI-0751) Phac Arg Gly-Gly-NH2 17.4 661.4/662.26 
92 (MI-0737) Phac Arg Gly-NH2 17.9 604.4/605.4 
93 (MI-0740) Phac Arg Ala-NH2 18 618.39/619.27 
94 (MI-0741) Phac Arg Val-NH2 20.5 646.42/647.34 
95 (MI-0739) Phac Arg Tle-NH2* 22.2 660.44/661.35 
96 (MI-0738) Phac Arg Pro-NH2 19.6 644.4/645.36 
97 (MI-0752) Phac Arg DAla-NH2 18.06 618.39/619.52 
98 (MI-0753) Phac Arg Sar-NH2* 18.3 618.39/619.37 
99 (MI-0754) Phac Arg Gaba-NH2* 18.1 632.41/633.29 
100 (MI-0755) Phac Arg Aca-NH2* 19.9 660.44/661.37 
101 (MI-0756) Phac Arg NH2 17.7 547.35/548.3 
102 (MI-0742) 3,4-dichloro-Phac Arg Gly-NH2 25.4 672.3/673.22 
103 (MI-0757) 3,4-dichloro-Phac Arg NH2 25.8 615.28/616.13 
104 (MI-0763) Phac hArg NH2 18.3 561.37/562.25 
105 (MI-0762) 3,4-dichloro-Phac hArg NH2 28.2 629.29/630.12 
 
*Tle = tert-leucine, Sar = sarcosine (2-(Methylamino)acetic acid), Gaba = γ- aminobutyric 
acid, Aca = ε-Aminocaproic acid 
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5.3.11 Synthesis of cyclic peptides 106-111 
Inhibitor 106 and related intermediates (Indentical strategy shown in Scheme 3.7) 
3-NH2-Phac-Lys(Boc)-Lys(Boc)-Arg(Pbf)-Gaba-OH × TFA 106a 
N
H
H
N
N
H
O
HN
O
NH
O
O
O
O
O
H
N
O
NH
HN NH
SO O
O
OH
O
H2N
x TFA
 
0.1 g of 2-Cl-tritylchlorid resin (1.55 mmol/g) was loaded with Fmoc-Gaba-OH 
according to method A. The Fmoc group was cleaved using 20 % piperidine in DMF, 
followed by multiple washing with DMF. The following residues Fmoc-Arg(Pbf)-OH, 
Fmoc-Lys(Boc)-OH and Fmoc-3-amino-Phac-OH (PolyPeptide) were coupled by 
standard Fmoc-SPPS as described in method C. The peptide was cleaved from resin 
according to method E generating the side-chain protected intermediate 106a. This 
derivative was used for the synthesis of compounds 106b and 106c without further 
purification. 
Yield: 119 mg (0.097 mmol), yellowish oil. 
HPLC: 51.7 % B (purity: 94.3%). 
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3-NH2-Phac-Lys-Lys-Arg-Gaba-OH × 4 TFA 106b 
N
H
H
N
N
H
O
NH2
O
NH2
O
H
N
O
NH
H
2
N NH
OH
O
H2N
x 4 TFA
 
Compound 106a was deprotected by treating with TFA as described in method I. The 
peptide was precipitated by diethyl ether. After centrifugation, the precipitate was 
washed with diethyl ether, and dried in vacuum. Intermediate 106b was purified by 
preparative HPLC, and lyophilized from water. 
Yield: 18.mg (0.016 mmol), white lyophilized powder. 
HPLC: 13.3 % B (purity: 99 %). 
3-NH-Phac-Lys(Boc)-Lys(Boc)-Arg(Pbf)-Gaba- 106c
 
NH
HN
HN
HN
NH
NH
HN
NH
HN
O
O O
O
HNO
Pbf
Boc
Boc
 
72.8 mg of the linear intermediate 106a (0.06 mmol) was dissolved in ~ 70 mL DMF 
and treated with 3 equiv Bop and initially with 3 equiv of DIPEA as described in 
method Q. After completion of the reaction, the DMF was removed in vacuum and the 
remaining oil was used without further purification for the synthesis of inhibitor 106. 
Yield: 60.mg (0.055 mmol), yellowish oil. 
HPLC: 62.4 % B (purity:62.4%). 
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3-NH-Phac-Lys-Lys-Arg-Gaba- 106x 3 TFA
 
NH
HN
HN
HN
NH
NH2
HN
H2N
H2N
O
O O
O
HNO
x 3 TFA  
30 mg of the crude intermediate 106c was treated with TFA as described in method I. 
The peptide was finally precipitated by diethyl ether. After centrifugation, the 
precipitate was washed with diethyl ether, and dried in vacuum. The inhibitor was 
purified by preparative HPLC and lyophilized from water. 
Yield: 21.4 mg (0.022 mmol), white lyophilized powder. 
HPLC: 18 % B (purity: 93.1%). 
Inhibitor 107 and related intermediates, see Scheme 3.7. 
3-NH2-CH2-Phac-Lys(Boc)-Lys(Boc)-Arg(Pbf)-Gaba × TFA 107a 
N
H
H
N
N
H
O
HN
O
NH
O
O
O
O
O
H
N
O
NH
HN NH
SO O
O
OH
O
H2N
x TFA
 
This intermediate was prepared in analogy to compound 106a, whereby Fmoc-3-NH-
CH2-Phac-OH (PolyPeptide) was used for the coupling of the terminal P4 residue. 
Yield: 123 mg (0.1 mmol), yellowish oil. 
HPLC: 51.6 % B (purity: 83.1 %). 
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3-NH2-CH2-Phac-Lys-Lys-Arg-Gaba × 4 TFA 107b 
N
H
H
N
N
H
O
NH2
O
NH2
O
H
N
O
NH
H2N NH
OH
O
H2N
x 4 TFA
 
Approximately one third of the intermediate 107a was deprotected in analogy to the 
synthesis of compound 106b. 
Yield: 20.4.mg (0.018 mmol), white powder. 
HPLC: 14.2 % B (purity: 99%) 
3-NH-CH2-Phac-Lys(Boc)-Lys(Boc)-Arg(Pbf)-Gaba- 107c
 
NH
HN
HN
NH
NH
HN
NH
HN
O
O O
O
HN
O
Pbf
Boc
Boc NH
 
Intermediate 107c was prepared in analogy to compound 106c from approximately two 
third of intermediate 107a. The oily residue remaining after evaporation, was used for 
final deprotection described in the next step. 
Yield: 64 mg (0.058 mmol), yellowish oil. 
HPLC: 61.9 % B (purity: 88.9 %). 
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3-NH-CH2-Phac-Lys-Lys-Arg-Gaba- 107x 3 TFA
NH
HN
HN
NH
NH2
HN
H2N
H
2
N
O
O O
O
HN
O
NH
x 3 TFA
 
50 mg of the crude intermediate 107c (0.045 mmol) was treated with TFA as described 
in method I. The peptide was finally precipitated by diethyl ether. After centrifugation, 
the precipitate was washed with diethyl ether, and dried in vacuum. The inhibitor was 
purified by preparative HPLC, and lyophilized from water. 
Yield: 26 mg (0.026 mmol), white lyophilized powder. 
HPLC: 18.1 % B (purity: 96.2 %). 
Synthesis of cyclic peptides 108-111 and related intermediates (Scheme 3.8) 
Intermediates 108a-111a 
0.1 g of 2-Cl-tritylchlorid resin (1.55 mmol/g) was loaded with Boc-Lys(Fmoc)-OH, 
Boc-D-Lys(Fmoc)-OH, Boc-Orn(Fmoc)-OH or Boc-D-Orn(Fmoc)-OH according to the 
method A. The Fmoc group of the lysine or ornithine side chain was cleaved using 20% 
piperidine in DMF as described in method C. After washing, the following residues (2 x 
Fmoc-Lys(Cbz)-OH and Fmoc-3-NH2-CH2-Phac-OH) were sequentially coupled to the 
free side chain amino group of the -Boc-protected lysine or ornithine residues 
(Scheme 3.10) on the resin using a standard SPPS Fmoc-protocol as described in 
method C. After removal of the terminal Fmoc-group the side chain Cbz- and Boc-
protected peptide was cleaved from resin under mild acidic conditions according to 
method D. After evaporation of the solvent the intermediates 108a-111a were used for 
the synthesis of intermediates 108b-111b without further purification. The analytical 
data of the derivatives 108a-111a are shown in the Table 5.13. 
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Table 5.13: Analytical characterization of intermediates 108a - 111a having the general formula. 
HN
O
N
H
HN
Cbz
O
H
N
HN
Cbz
O
x TFA
NH2
*HN
OH
OBoc
n
 
No. n * HPLC (% B) Purity (%) 
108a 2 L 49.9 76 
109a 2 D 49.9 79 
110a 1 L 49.3 67 
111a 1 D 49.2 82.9 
The cyclic intermediates 108b, c, d-111 b, c, d and the corresponding inhibitors 
108-111 
The intermediates 108a-111a were dissolved in DMF (100 mL/0.1mmol), and treated 
with 3 equiv Bop and initially with 3 equiv DIPEA according to method Q. After 
completion of the reaction, the DMF was removed in vacuum to obtain the cyclic 
peptides 108b-111b still containing the Cbz and Boc protection as yellowish oil.  
The Boc group of these derivatives 108b-111b was cleaved by TFA as described in 
method I. The TFA was removed in vacuum to obtain the Cbz protected intermediates 
108c-111c. 
Compounds 108c-111c were dissolved with 1mL DMF and treated with 2 equiv of the 
guanylation reagent N,N’-di-Boc-1Hpyrazole-1-carboxamidine and 3 equiv DIPEA as 
described in method N to give the Boc protected guanidine intermediates 108d-111d. 
Final removal of the Cbz- and Boc-protection was achieved by treatment with ~ 2 ml 
32% HBr/acetic acid according to method G, which provided the crude inhibitors 108-
111. The solvent was partially removed in vacuum and the products were precipitated 
by diethyl ether. After centrifugation, the precipitate was washed with diethyl ether, and 
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dried in vacuum. The inhibitors were purified by preparative HPLC, and lyophilized 
from water. The analytical data of the cyclic peptides 108-111 and their related 
intermediates are summarized in Table 5.14. 
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Table 5.14: Analytical characterization of inhibitors 108-111 and their related intermediates with index b, 
c, and d, having the general formula.  
N
H
N
H
NH O
O
O
HN
HN
R2
R2
O
HN
H
N
n
R1
*
 
No. n R1 R2 * 
HPLC 
(% B) 
Purity 
(%) 
MS (calcd/found) 
(M+H)
+
 
108 (MI-0758) 2 
NH2
NH

 
H L 17.5 96.0 573.38/574.3 
108b 2 Boc Cbz L 60.9 - n.d. 
108c 2 H Cbz L 46.7 - n.d. 
108d 2 
H
N
N

Boc
Boc  
Cbz L 67.2 - n.d. 
109 (MI-0759) 2 
NH2
NH

 
H D 17.6 87.0 573.38/574.3 
109b 2 Boc Cbz D 60.6 - n.d. 
109c 2 H Cbz D 46.9 - n.d. 
109d 2 
H
N
N

Boc
Boc  
Cbz D 66.5 - n.d. 
110 (MI-0760) 1 
NH2
NH

 
H L 17.0 95.5 559.36/560.3 
110b 1 Boc Cbz L 59.7 - n.d. 
110c 1 H Cbz L 46.8 - n.d. 
110d 1 
H
N
N

Boc
Boc  
Cbz L 66.5 - n.d. 
111 (MI-0761) 1 
NH2
NH

 
H D 17.1 86.3 559.36/560.3 
111b 1 Boc Cbz D 59.5 - n.d. 
111c 1 H Cbz D 47.0 - n.d. 
111d 1 
H
N
N

Boc
Boc  
Cbz D 17.1 - n.d. 
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5.3.12 Synthesis of substrates 112-114 and related intermediates 
Intermediates 112a and 114a 
N
H
H
N
OH
O
HN
O
NH
O
O
O
O
O
   
N
H
H
N
OH
O
HN
O
NH
O
O
O
O
O
H
N
O
 
         112a      114a 
0.1 g of 2-Cl-tritylchlorid resin (1.55 mmol/g) was loaded with Fmoc-Lys(Boc)-OH 
according to method A. Afterwards, the following Fmoc amino acids and phenylacetyl 
residues were coupled by standard Fmoc SPPS according to method C. The peptides 
were cleaved from resin under mild acidic conditions as described in method D to give 
derivatives Phac-Lys(Boc)-Lys(Boc)-OH (112a) and Phac-Leu-Lys(Boc)-Lys(Boc)-OH 
(114a), respectively. Compound 112a was coupled with H-Arg-pNA  2 HCl (Orpegen, 
Heidelberg) or H-Arg-AMC  2 HCl (Pentapharm, Basel, Switzerland) according to 
method F to provide intermediates 112b and 113b, respectively. The compound 114a 
was also coupled with H-Arg-AMC × 2 HCl as described in method F to give the 
intermediate 114b with the general formaula and Phac-Leu-Lys(Boc)-Lys(Boc)-Arg-
AMC. All the derivatives 112b-114b were Boc-deprotected using 90% TFA according 
to method I to give the compounds 112-114. The substrates were finally precipitated in 
diethyl ether. After centrifugation, the precipitate was washed with diethyl ether, and 
dried in vacuum. The products were purified by preparative HPLC, and lyophilized 
from water. The analytical data of the derivatives 112a, b, 113b and 114a, b and the 
corresponding substrates 112-114 are shown in the Table 5.15.  
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Table 5.15: Analytical characterization of the substrates 112-114 and their related intermediates. 
No. sequence 
HPLC  
(% B) 
Purity 
(%) 
MS 
(calcd/found) 
(M+H)
+
 
112 (MI-0744) Phac-Lys-Lys-Arg-pNA  3TFA 27.1 98 668.4/669.3 
112a Phac-Lys(Boc)-Lys(Boc)-OH 55.3 83 n.d. 
112b Phac-Lys(Boc)-Lys(Boc)-Arg-pNA  HCl 54.7 - n.d. 
113 (MI-0749) Phac-Lys-Lys-Arg-AMC  3TFA 27 98.5 705.4/706.4 
113b Phac-Lys(Boc)-Lys(Boc)-Arg-AMC  HCl 52.5 - n.d. 
114 (MI-0624) Phac-Leu-Lys-Lys-Arg-AMC  3TFA 33.5 99 640.4/641.2 
114a Phac-Leu-Lys(Boc)-Lys(Boc)-OH 60.9 91.8 n.d. 
114b Phac-Leu-Lys(Boc)-Lys(Boc)-Arg-AMC  HCl 57.3 - n.d. 
5.4 Stability tests of peptides 91-105 
1 mM stock solutions of the peptides, substrates and their possible cleavage products 
Phac-Lys-Lys-Arg-OH, p-nitroaniline, and 7-amino-4-methylcoumarin were prepared 
in WNV protease assay buffer (see paragraph 5.2.1). 175 µL of these 1 mM solutions 
were mixed with 25 µL WNV protease stock ( 160 nM) providing a total volume of 
200 µL. The resulting mixtures contained 0.875 mM of the peptides or derivatives and 
20 nM of the WNV protease. After 1 h, 4 h and 8 h of incubation with the enzyme, 
50 µL of each incubation mixture was withdrawn and further diluted with 700 µL of a 
solution prepared from ACN/H2O/TFA (49.5/49.5/1, v/v/v) to stop the enzymatic 
reaction. Finally, 150 µL of this mixture, containing 58.3 µM of the peptides or 
derivatives were injected to HPLC. 
To get reference HPLC-chromatograms of all compounds under identical concentrations 
without any influence of the WNV protease, 25 µl of buffer was added instead of the 
enzyme to the 175 µL of the 1 mM stock solutions of the peptides in the initial step. The 
following steps were performed as described above. 
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5.5 Crystal structure determination 
The crystallization of the WNV NS2B-NS3 protease in complex with inhibitor 77 (MI-
0683), the data collection, structure determination  and refinement was performed by 
Caroline Haase in the group of Prof. Dr. Rolf Hilgenfeld (Institute of Biochemistry, 
Ratzeburger Allee 160, Lübeck). These results were recently published.
90
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